# Chapter 119: Other (or Unknown) Substance Intoxication

## The Biological and Neurological Basis of Other (or Unknown) Substance Intoxication

## Introduction

Other (or Unknown) Substance Intoxication represents a significant diagnostic and clinical challenge in emergency medicine and psychiatry (Sarkar et al., 2023). This diagnostic category, as outlined in frameworks like the DSM-5, encompasses substance-induced disorders where the intoxicating agent is not one of the explicitly defined substance classes or is simply unidentified (Daley & Douaihy, 2019; Wakefield, 2015). Intoxication is defined as a transient condition following the administration of a psychoactive substance, resulting in clinically significant disturbances in consciousness, cognition, perception, affect, behavior, or other psychophysiological functions (Sarkar et al., 2023; Franklin, 1995). The clinical presentation is often that of an acute encephalopathy, delirium, or acute confusional state, characterized by a sudden change in mental status with a fluctuating course (Schildkrout, 2014; Todd & Teale, 2017; Lipowski, 1987).

The difficulty in managing these cases stems from the unknown nature of the substance or substances involved (Sarkar et al., 2023). The patient may be unable or unwilling to provide a reliable history, and standard toxicological screens may not detect the causative agent, a problem exacerbated by the continuous emergence of novel psychoactive substances (NPS) (Wojtyła-Buciora et al., 2023; Scotton et al., 2019). Consequently, the clinical picture can be complex and heterogeneous, potentially mimicking a wide range of primary psychiatric or neurological disorders (Griswold et al., 2015; Kokurcan & Atbaşoğlu, 2015). Symptoms can range from profound central nervous system (CNS) depression and coma (Ciszowski & Mietka-Ciszowska, 2013) to severe psychomotor agitation, psychosis, and autonomic instability (Vilke & Ly, 2022; Pérez et al., 2022).

Despite the etiologic uncertainty, the biological and neurological manifestations of intoxication represent a final common pathway of brain dysfunction (Kryzhanovskiĭ, 2002). All psychoactive substances exert their effects by altering the normal functioning of the nervous system, producing a change in biological function, mood, perception, and consciousness (Schreiber, 2022; Moncrieff, 2008). This chapter aims to provide a comprehensive overview of the biological and neurological basis of Other (or Unknown) Substance Intoxication. By synthesizing evidence from known psychoactive agents and general principles of neuropharmacology, neurotoxicity, and systems neuroscience, we can construct a framework for understanding the potential mechanisms at play. This chapter will explore the disruption of key neurotransmitter systems, the involvement of specific neural circuits, genetic and molecular underpinnings of vulnerability and response, structural and functional brain changes, and the implications of these biological alterations for clinical presentation, management, and long-term outcomes. Understanding these fundamental mechanisms is paramount for clinicians faced with the diagnostic ambiguity and potential lethality of intoxication by an unknown substance (Sarkar et al., 2023; Salaspuro, 2009).

## Neurobiological Systems

The clinical manifestations of Other (or Unknown) Substance Intoxication are the direct result of a substance's interaction with the complex neurobiological machinery of the central nervous system (CNS) (Schreiber, 2022). Psychoactive drugs produce altered states of consciousness by modulating the activity of various neurotransmitter systems, thereby disrupting the delicate balance of neural excitation and inhibition that governs normal brain function (Willner, 1984; Moncrieff, 2008). The heterogeneity of symptoms observed in unknown intoxications reflects the vast array of potential pharmacological targets and the intricate interplay between different neurochemical pathways (Ferner et al., 1995; Abou‐Donia, 2015).

### Neurotransmitter Systems and Neuropharmacology

The brain's communication network relies on a diverse set of chemical messengers, or neurotransmitters, which are primary targets for psychoactive substances (Ebenezer, 2015). An unknown intoxicating agent is likely acting as an agonist, antagonist, partial agonist, reuptake inhibitor, or releasing agent at one or more receptor systems, leading to a cascade of downstream effects (Mailman & Murthy, 2010; Schreiber, 2022).

**The Dopaminergic System:** The mesolimbic dopamine pathway is central to the brain's reward, motivation, and reinforcement circuitry (Koob, 2013; Beninger, 2018; Heinz, 2017). Virtually all drugs with abuse potential, including stimulants like cocaine and amphetamines, increase dopamine release in the nucleus accumbens, which is a key mechanism underlying their reinforcing and euphoric effects (Parolaro et al., 2005; Scuvée‐Moreau, 2013; Roberts & Koob, 1997). An unknown substance with stimulant properties would likely produce psychomotor activation, euphoria, increased energy, and alertness by enhancing dopaminergic neurotransmission (Vilke & Ly, 2022; Parrott, 2015). Excessive dopamine activity, however, is strongly linked to the development of psychosis, characterized by paranoia, delusions, and hallucinations (Ereshefsky et al., 1990; Mauri, 2016). Therefore, a patient presenting with acute psychosis after consuming an unknown substance may be experiencing profound dopaminergic hyperactivity (Avellaneda Ojeda et al., 2023; Palmer, 2016). Chronic stimulation of this system can lead to neuroadaptive changes, such as D2 receptor supersensitivity, which may contribute to psychosis and movement disorders (Seeman & Seeman, 2011; Kane, 1997).

**The Serotonergic (5-HT) System:** The serotonin system is a critical modulator of mood, anxiety, sleep, appetite, and perception (Stanford, 2001; Liu et al., 2019). Many substances, including psychedelics like LSD and MDMA ("ecstasy"), exert their primary effects through this system, particularly via agonism at 5-HT2A receptors (Pechnick et al., 2014; Brogaard, 2013; Cole & Katz, 1964). Intoxication with an unknown serotonergic agent could manifest with altered perceptions (illusions, hallucinations), mood elevation, and feelings of empathy or closeness to others (Cole & Katz, 1964; Krishnan, 2024).

A critical and potentially fatal consequence of excessive serotonergic activity is Serotonin Syndrome (SS), or serotonin toxicity (Scotton et al., 2019; Iqbal, 2015). This toxidrome is a predictable consequence of serotonergic excess and is not an idiosyncratic reaction (Rahmani et al., 2011; Scotton et al., 2019). It is characterized by a clinical triad of altered mental status (agitation, confusion), autonomic hyperactivity (hyperthermia, tachycardia, diaphoresis, diarrhea), and neuromuscular abnormalities (tremor, clonus, myoclonus, hyperreflexia) (Gordon & Leder, 2012; Lane & Baldwin, 1997; Spreux‐Varoquaux, 2014). SS is most often caused by a combination of serotonergic drugs, such as a selective serotonin reuptake inhibitor (SSRI) and a monoamine oxidase inhibitor (MAOI), but can also occur with a single agent, an overdose, or interactions with NPS (Scotton et al., 2019; Thanacoody, 2007; Yates et al., 2011). The activation of 5-HT1A and 5-HT2A receptors is considered predominant in its pathophysiology (Scotton et al., 2019; Rizal & Fiana, 2019). Given the wide range of prescribed medications, illicit drugs, and herbal products with serotonergic properties, SS is a crucial differential diagnosis in any patient presenting with this triad after consuming an unknown substance (Badar, 2024; Sahiner & Akı, 2009).

**The GABAergic System:** The γ-aminobutyric acid (GABA) system is the primary inhibitory neurotransmitter system in the CNS (Söderpalm, 2002). Substances like alcohol, benzodiazepines, and barbiturates enhance GABAergic transmission, leading to CNS depression (Tseng et al., 2020; Söderpalm, 2002). Intoxication with an unknown GABAergic agent would likely present with sedation, somnolence, ataxia, slurred speech, psychomotor retardation, and in severe cases, respiratory depression, stupor, or coma (Ciszowski & Mietka-Ciszowska, 2013; Wijdicks, 2025; Sarkar et al., 2023). The sedative effects of these drugs can be additive, and co-ingestion with other CNS depressants significantly increases the risk of life-threatening complications (Lee‐Chiong, 2008; Paillé et al., 1993). Abrupt cessation of chronic use leads to a hyperexcitable state, manifesting as a withdrawal syndrome with anxiety, tremor, and seizures (Trevisan et al., 1998; Becker, 1998; Kašpárek et al., 2014).

**The Glutamatergic System:** As the primary excitatory neurotransmitter, glutamate is essential for synaptic plasticity, learning, and memory (Becker & Redmond, 2002). However, excessive glutamatergic activity is neurotoxic, a phenomenon known as excitotoxicity, which can lead to neuronal death (Pujol & Puel, 1999; Volpe, 1997). Seizures are a manifestation of excessive, hypersynchronous neuronal discharge and can be a feature of intoxication with certain substances (e.g., stimulants) or withdrawal from depressants (Stafstrom, 1995; Brust, 2002). An unknown substance could induce seizures by promoting glutamate release or blocking GABAergic inhibition (Hantson, 2004). Conversely, drugs like ketamine and phencyclidine (PCP) act as antagonists at the N-methyl-D-aspartate (NMDA) glutamate receptor, producing dissociative states characterized by depersonalization, derealization, amnesia, and sometimes psychosis (Good, 1989; Bokor & Anderson, 2014; Pechnick et al., 2014).

**Other Neurotransmitter Systems:** The clinical picture can also be shaped by effects on other systems. Disruption of the **cholinergic system** can produce an anticholinergic toxidrome (delirium, mydriasis, tachycardia, hyperthermia, urinary retention, dry skin), a medical emergency (Çiçek et al., 2022; Grover et al., 2022). The **noradrenergic system**, involved in arousal and the "fight-or-flight" response, is activated by stimulants, contributing to tachycardia, hypertension, and agitation (Swann, 2012; Varı̀ et al., 2018). The **endogenous opioid system** is the target of narcotics like heroin and prescription painkillers, and intoxication with an unknown opioid would present with the classic triad of CNS depression, respiratory depression, and miosis (Sarkar et al., 2023). The **endocannabinoid system** is also a target for drugs of abuse and plays a role in motivation and reward (Parolaro et al., 2005).

In summary, the neuropharmacology of unknown substance intoxication is a process of deduction based on the observed clinical syndrome. The constellation of symptoms—be it sedation, stimulation, psychosis, or dissociation—provides crucial clues to the primary neurotransmitter system being disrupted, guiding both diagnosis and emergency management (Sarkar et al., 2023; Salaspuro, 2009).

## Genetic and Molecular Basis

The acute response to an intoxicating substance and an individual's long-term vulnerability to developing a substance use disorder (SUD) are shaped by a complex interplay of genetic predispositions and molecular adaptations within the brain (Daley & Douaihy, 2019; Winters & Ingwalson, 2022). While Other (or Unknown) Substance Intoxication is an acute event, the underlying biological landscape that determines its severity and nature is influenced by these enduring factors.

### Genetic Factors and Heritability

A significant genetic component contributes to the risk for developing SUDs (Blum & Trachtenberg, 1988; Tiganov, 2013). This heritability influences not only the propensity for addiction but also the individual response to acute drug effects (Koob et al., 2015). For an unknown substance, these genetic variations can result in unpredictable and heterogeneous clinical presentations (Ferner et al., 1995).

A critical area of genetic influence is in pharmacokinetics, particularly the enzymes responsible for drug metabolism (Shah, 2005). The cytochrome P450 (CYP) enzyme system in the liver is responsible for the metabolism of a vast number of xenobiotics, including most psychoactive drugs (Grannell, 2020). Genetic polymorphisms in CYP genes, such as CYP2D6, are common and can lead to clinically significant differences in metabolic capacity (Gram et al., 1993). Individuals can be classified as poor, intermediate, extensive, or ultrarapid metabolizers. A poor metabolizer may accumulate a drug to toxic levels even at standard doses, leading to severe or unexpected intoxication (Gram et al., 1993; Shah, 2005). Conversely, an ultrarapid metabolizer might experience a reduced effect or a more rapid buildup of a toxic metabolite (Scelsi & Candura, 2013). When the intoxicating substance is unknown, the patient's underlying metabolic phenotype is also unknown, creating a high-risk situation where a seemingly "recreational" dose could have life-threatening consequences (Boyer & Blumhardt, 1992; Shah, 2005). Genetic factors also influence pharmacodynamics, affecting the structure and function of neurotransmitter receptors, transporters, and signaling molecules, thereby altering an individual's sensitivity to a drug's effects (Koob et al., 2015).

### Molecular Mechanisms and Neuroplasticity

The brain is not a static organ; it dynamically adapts to pharmacological challenges through processes of neuroplasticity (Kryzhanovskiĭ, 2002). Repeated exposure to psychoactive substances triggers a cascade of molecular and cellular adaptations aimed at maintaining homeostasis in the face of neurochemical disruption (Goldstein, 2001; Hayes & Lingford‐Hughes, 2023). These changes are the foundation of tolerance, dependence, and withdrawal (Franklin, 1995).

**Tolerance** develops when a given dose of a drug produces a lesser effect, requiring larger amounts to achieve the initial intoxication (Franklin, 1995; Tseng et al., 2020). This can occur through pharmacokinetic mechanisms (e.g., enzyme induction leading to faster drug clearance) or pharmacodynamic mechanisms (e.g., downregulation or desensitization of receptors) (Goldstein, 2001; Shah, 2005). **Dependence** is an adaptive state that manifests as a withdrawal syndrome upon cessation of drug use (Franklin, 1995; Hughes et al., 1994). The symptoms of withdrawal are typically opposite to the acute effects of the drug, reflecting the brain's homeostatic overcorrection (Goldstein, 2001). For instance, withdrawal from a CNS depressant like alcohol results in CNS hyperexcitability, including anxiety, tremors, and seizures (Trevisan et al., 1998; Yersin, 1999).

Another key molecular process is **sensitization**, or reverse tolerance, where repeated intermittent exposure to a drug leads to an augmented behavioral or physiological response (Robinson, 2014; Kalivas, 2003). This is particularly relevant for the psychomotor and psychotic effects of stimulants and is thought to be a core mechanism in the development of compulsive drug-seeking (Leyton, 2022; Robinson et al., 2018). Sensitization involves long-lasting changes in gene expression and synaptic strength within the mesolimbic dopamine system (Kalivas et al., 2003).

These neuroadaptive processes are driven by changes at the molecular level, including alterations in second messenger systems, protein phosphorylation, and the expression of immediate early genes and transcription factors that regulate the synthesis of receptors, enzymes, and other crucial proteins (Kalivas et al., 2003). For example, stress and drugs of abuse can induce epigenetic modifications, such as changes in DNA methylation and histone acetylation, which lead to enduring alterations in gene expression and contribute to the vulnerability to addiction and relapse (Coelho et al., 2023; Ventriglio et al., 2015). These molecular legacies mean that an individual with a history of substance use may have a fundamentally altered brain, which could react to an unknown substance in an exaggerated or atypical manner due to pre-existing sensitization or tolerance (Kalivas, 2003). Therefore, the biological context of an unknown substance intoxication includes not only the acute pharmacology of the drug but also the entire history of the individual's genetic makeup and drug-induced neuroplasticity.

## Brain Structure and Function

The signs and symptoms of Other (or Unknown) Substance Intoxication arise from the temporary disruption of function within specific brain regions and the neural circuits that connect them (Abou‐Donia, 2015). While acute intoxication is primarily a state of functional, reversible brain dysfunction (Rigaud et al., 2006), the patterns of impairment provide crucial insights into the neuroanatomical substrates being affected.

### Brain Regions, Neural Circuits, and Functional Connectivity

Different classes of psychoactive substances have distinct profiles of action on brain circuitry, and the clinical presentation of intoxication often points to the primary systems involved (Ferner et al., 1995).

**Cortical and Subcortical Systems:** Consciousness itself depends on the integrity of both the cerebral cortex and subcortical arousal systems, particularly the brainstem reticular activating system (Yamauchi, 1998; Bansal et al., 2014). Many intoxicating substances, especially CNS depressants like alcohol, barbiturates, and benzodiazepines, cause a global suppression of cortical function and brainstem arousal networks, leading to a spectrum of impairment from lethargy and confusion to stupor and coma (Ciszowski & Mietka-Ciszowska, 2013; Gluncić, 2024; Horton, 1980). This state of unconsciousness is a form of reversible coma, pathologically distinct from structural brain injury but functionally similar in its acute presentation (Horton, 1980; Ciszowski & Mietka-Ciszowska, 2013). The clinical assessment of consciousness level is therefore a primary indicator of the severity of intoxication (Sarkar et al., 2023).

**The Reward Circuitry:** The mesolimbic and mesocortical dopamine pathways, originating in the ventral tegmental area and projecting to the nucleus accumbens, amygdala, and prefrontal cortex (PFC), form the brain's core reward circuitry (Koob, 2013; Heinz, 2017; Beninger, 2018). This system is crucial for processing natural rewards and motivating survival-related behaviors (Meléndez & Kalivas, 2008). Addictive drugs hijack this system, causing supraphysiological increases in dopamine that produce euphoria and powerfully reinforce drug-taking behavior (Roberts & Koob, 1997; Scuvée‐Moreau, 2013). Intoxication with stimulants like cocaine or amphetamines reflects intense activation of this circuit, leading to elevated mood and increased goal-directed activity (Vilke & Ly, 2022; Krishnan, 2024).

**The Prefrontal Cortex (PFC) and Executive Function:** The PFC is the seat of higher-order cognitive processes known as executive functions, including planning, decision-making, working memory, and impulse control (Sun, 2018; Nigg, 2003). This region is highly sensitive to the effects of intoxicating substances (Alfonso‐Loeches & Guerri, 2011). Alcohol and other drugs acutely impair PFC function, leading to the disinhibition, poor judgment, impulsivity, and risk-taking behavior characteristic of many intoxications (Noël et al., 2010; Swann, 2012). This functional "hypofrontality" disrupts the top-down control that the PFC normally exerts over subcortical motivational and emotional drives (Fries, 2013).

**Limbic Structures and Emotion:** The amygdala and hippocampus are key limbic structures involved in processing emotion and memory, respectively (Goodman et al., 2017). The anxiolytic effects of substances like alcohol and benzodiazepines are mediated, in part, by suppressing activity in the amygdala (Tseng et al., 2020). Conversely, stimulant intoxication or withdrawal from depressants can lead to amygdala hyperactivity, manifesting as anxiety, panic, or paranoia (Sarkar et al., 2023). The hippocampus is particularly vulnerable to the effects of alcohol, which can disrupt memory consolidation and lead to amnesic episodes or "blackouts" (Crichton & Ward, 2013; DeJong, 1969).

**The Cerebellum and Motor Control:** The cerebellum is critical for coordinating voluntary movement, balance, and posture (Leiguarda, 2003). Ataxia, or uncoordinated movement, is a hallmark sign of intoxication with CNS depressants (Kidd et al., 2023; Pattanashetti & Doddanavar, 2022). This manifests as an unsteady gait, slurred speech (dysarthria), and clumsiness, reflecting the substance's disruptive effect on cerebellar circuitry (Japardi, 2002).

### Neuroimaging Findings

While functional neuroimaging techniques could theoretically reveal the acute effects of unknown substances on brain activity and connectivity, their use in the emergency setting is impractical and rarely performed for diagnostic purposes in intoxication (Sarkar et al., 2023). The primary role of neuroimaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), is to exclude other causes of altered mental status that can mimic intoxication (Grover et al., 2022). These include traumatic brain injury (TBI), stroke (ischemic or hemorrhagic), intracranial hemorrhage, brain tumors, or CNS infections like meningitis or encephalitis (Sarkar et al., 2023; Griswold et al., 2015; Hocker, 2015).

In cases of chronic substance abuse, structural neuroimaging may reveal long-term consequences such as cerebral atrophy, ventricular enlargement, or white matter changes (Page, 1983; Crichton & Ward, 2013). However, in an acute, first-time, or unknown intoxication, structural imaging is typically normal (Brody, 2019). The clinical syndrome is one of functional, not structural, disruption (Kryzhanovskiĭ, 2002). The concept of diaschisis, where a focal lesion causes a remote depression of function, may be analogous to intoxication, where a widespread pharmacological insult leads to a global depression of cerebral metabolism and function (Meyer et al., 1993). In severe cases, such as anoxic brain injury secondary to respiratory depression from an opioid overdose, neuroimaging may later show evidence of hypoxic-ischemic damage, particularly in vulnerable areas like the hippocampus, basal ganglia, and cerebellum (Fugate, 2019; Miller & Latal, 2009).

## Developmental Neurobiology

The neurobiological effects of intoxicating substances are not uniform across the lifespan; they are profoundly influenced by the developmental stage of the brain (Dubovický, 2010). Both the immature, developing brain of childhood and adolescence and the aging brain of older adulthood exhibit unique vulnerabilities that can shape the presentation and consequences of intoxication (Gram et al., 1993; Hyytiä, 2015).

### Vulnerability in Adolescence and Critical Periods

Adolescence is a critical period of neurodevelopment characterized by significant synaptic pruning, myelination, and maturation of key neural circuits, particularly within the prefrontal cortex (PFC) and limbic system (Quartini et al., 2018). This ongoing development makes the adolescent brain uniquely susceptible to the neurotoxic and disruptive effects of psychoactive substances (Hyytiä, 2015; McArdle & Angom, 2012).

Exposure to drugs of abuse during this sensitive window can interfere with normal brain maturation processes (Hyytiä, 2015; Quartini et al., 2018). For example, alcohol and cannabis use can impair the development of the PFC, a region critical for executive functions like decision-making, impulse control, and planning (Hyytiä, 2015; Alfonso‐Loeches & Guerri, 2011). This disruption can have long-lasting consequences, potentially leading to persistent cognitive deficits and an increased risk for developing substance use disorders and other psychiatric conditions later in life (Winters & Ingwalson, 2022; Brady & Sinha, 2005). The still-developing reward and emotional regulation circuits are also highly sensitive to pharmacological manipulation, which may explain the heightened risk-taking and impulsive behaviors seen in intoxicated adolescents (Winters & Ingwalson, 2022; Daley & Douaihy, 2019). Therefore, an unknown substance intoxication in an adolescent may not only present with acute symptoms but also carries the risk of derailing crucial neurodevelopmental trajectories (Quartini et al., 2018).

### Vulnerability in Older Adulthood

Older adults represent another vulnerable population, though for different reasons (Gram et al., 1993). The aging process is associated with physiological changes that alter both the pharmacokinetics and pharmacodynamics of drugs (Palmieri, 1991). Reduced hepatic metabolism and renal clearance can lead to higher and more prolonged drug concentrations, increasing the risk of toxicity from standard doses (Gram et al., 1993; Kanellopoulos & Sánchez-Barranco Vallejo, 2019). Furthermore, age-related changes in the brain, such as neuronal loss and alterations in neurotransmitter systems, can increase sensitivity to the CNS effects of psychoactive drugs (Schweren, 2016).

Polypharmacy is a major contributing factor in this population (Karssemeijer et al., 2021). Many older adults take multiple medications for various chronic conditions, which significantly increases the potential for adverse drug-drug interactions that can precipitate or worsen an intoxicated state (Sarkar et al., 2023; Gram et al., 1993). These factors make older adults particularly susceptible to developing delirium (an acute confusional state) in response to a wide range of medications, infections, or metabolic disturbances (Lindesay & Macdonald, 1997; Francis, 1997; Romesser, 2017). An unknown substance intoxication in an elderly individual is highly likely to manifest as delirium, characterized by fluctuating consciousness, inattention, and cognitive impairment (Schildkrout, 2014; Todd & Teale, 2017). This can be easily mistaken for a progression of underlying dementia or another medical illness, complicating diagnosis and management (Francis, 1997; Kanellopoulos & Sánchez-Barranco Vallejo, 2019).

### Early Life and Prenatal Influences

The foundations for an individual's response to substances can be laid down even before birth (Dubovický, 2010). Prenatal exposure to substances like alcohol, nicotine, or illicit drugs can cause profound and permanent alterations in fetal brain development (Lockhart, 2001; Dubovický, 2010). These developmental disruptions can lead to a spectrum of neurodevelopmental disorders and create a lasting vulnerability to substance abuse and other psychiatric problems in later life (Winters & Ingwalson, 2022; Copeland‐Linder et al., 2017). Similarly, exposure to severe stress or trauma in early childhood can alter the development of stress-response systems, such as the hypothalamic-pituitary-adrenal (HPA) axis, and key neural circuits, which can also increase susceptibility to the effects of psychoactive substances in adulthood (Wiet, 2017; McEwen, 2003). Thus, the biological context for an acute intoxication is shaped by a long history of developmental influences, from the prenatal environment through childhood and adolescence, all of which can modulate an individual's response to an unknown substance.

## Treatment Mechanisms

The management of Other (or Unknown) Substance Intoxication is a medical emergency that prioritizes the stabilization of vital functions and the mitigation of life-threatening complications (Sarkar et al., 2023; Rigaud et al., 2006). The biological basis of treatment strategies revolves around counteracting the substance's acute neuropharmacological and systemic effects, even when the specific agent is unidentified (Salaspuro, 2009).

### Supportive Care: The Cornerstone of Management

For the vast majority of intoxications, the primary intervention is supportive care (Sarkar et al., 2023; Hantson, 2013). This approach is not passive but involves the active management of the "ABCs"—Airway, Breathing, and Circulation (Grover et al., 2022). Many substances, particularly CNS depressants, can cause respiratory depression, airway obstruction, and hypotension (Wijdicks, 2025; Ciszowski & Mietka-Ciszowska, 2013). Interventions such as endotracheal intubation and mechanical ventilation directly support respiratory function, preventing the catastrophic secondary brain injury that results from hypoxia and anoxia (Horton, 1980; Fugate, 2019). Intravenous fluids and vasopressors are used to counteract hypotension and maintain cerebral perfusion, which is critical for brain viability (Rigaud et al., 2006; Ramsay, 2014). This supportive framework allows the body's natural metabolic processes to clear the intoxicating substance, leading to the eventual reversal of the intoxicated state (Ciszowski & Mietka-Ciszowska, 2013).

### Pharmacological Antagonism

In specific instances where the class of substance is identified or strongly suspected, pharmacological antagonists can be used to directly reverse the drug's effects at the molecular level (Sarkar et al., 2023). These antagonists act as competitive inhibitors at the target receptor, displacing the intoxicating agonist and blocking its action.
*   **Naloxone** is a competitive antagonist at mu-opioid receptors and is the specific antidote for opioid overdose. Its administration can rapidly reverse the respiratory depression and coma characteristic of opioid intoxication (Monotti, 1993; Sarkar et al., 2023).
*   **Flumazenil** is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. It can reverse the sedative and respiratory depressant effects of benzodiazepines, although its use is cautioned in cases of mixed overdose or in patients with a history of seizures, as it can precipitate withdrawal seizures (Monotti, 1993; Sarkar et al., 2023).

The use of antagonists is a clear example of a treatment targeting a specific biological mechanism, but it is only possible when the substance's identity is reasonably certain (Monotti, 1993).

### Management of Agitation, Psychosis, and Seizures

Severe agitation and psychosis are common in intoxications with stimulants or hallucinogens and represent a state of CNS hyperexcitability (Vilke & Ly, 2022; Pérez et al., 2022). The primary pharmacological approach involves enhancing CNS inhibition. **Benzodiazepines** are often the first-line treatment, as they potentiate the effects of the inhibitory neurotransmitter GABA, which can calm agitation and reduce the risk of seizures regardless of the specific stimulant involved (Vilke & Ly, 2022; Sarkar et al., 2023). **Antipsychotic medications**, which primarily block dopamine D2 receptors, may also be used, but require caution (Grover et al., 2022). Their use in an unknown intoxication carries risks, such as lowering the seizure threshold, prolonging the QTc interval, or exacerbating an anticholinergic toxidrome (Haddad & Dursun, 2007; Lambert, 2007).

Seizures, whether caused by intoxication or withdrawal, are treated by stabilizing neuronal membranes and enhancing GABAergic inhibition (Stafstrom, 1995; Hantson, 2004). Benzodiazepines are the initial treatment of choice, followed by infusions of other antiseizure medications like phenytoin, levetiracetam, or barbiturates if seizures persist (Sabo-Graham & Seay, 1998; Al-Balawi et al., 2003; Lipatova et al., 2015).

### Management of Specific Toxidromes

Recognizing specific patterns of symptoms, or toxidromes, can guide treatment even when the exact substance is unknown (Sarkar et al., 2023).
*   **Serotonin Syndrome (SS):** Management focuses on discontinuing the offending agent(s) and providing supportive care (Scotton et al., 2019; Iqbal, 2015). Benzodiazepines are used to control agitation and neuromuscular hyperactivity (Ramachandran et al., 2018). In severe cases, **cyproheptadine**, a drug with antihistaminic and serotonin antagonist properties, may be administered to block 5-HT2A receptors and mitigate the toxicity (Yates et al., 2011; Scotton et al., 2019).
*   **Anticholinergic Syndrome:** This condition results from the blockade of muscarinic acetylcholine receptors. Besides supportive care, the specific antidote is **physostigmine**, a centrally acting acetylcholinesterase inhibitor (Cook & Spence, 1997). By preventing the breakdown of acetylcholine, physostigmine increases its availability to overcome the receptor blockade, thereby reversing the delirium and peripheral symptoms (Çiçek et al., 2022). Its use is reserved for severe cases due to potential side effects like bradycardia and seizures (Cook & Spence, 1997).

The biological rationale for treating unknown substance intoxication is thus a pragmatic application of neuropharmacological principles. It involves supporting compromised physiological systems while attempting to infer the disrupted neurotransmitter pathways from the clinical syndrome to guide more targeted, though often empirical, interventions (Salaspuro, 2009; Sarkar et al., 2023).

## Future Directions

The field of clinical toxicology is in a constant race to keep pace with the ever-evolving landscape of substance use, particularly the proliferation of novel psychoactive substances (NPS) (Wojtyła-Buciora et al., 2023). These "designer drugs" often have unknown pharmacological profiles, unpredictable toxicities, and are not detected by standard screening methods, posing a formidable challenge to the diagnosis and management of Other (or Unknown) Substance Intoxication (Venkataraman et al., 2020; Wojtyła-Buciora et al., 2023). Future research must focus on bridging the gap between the emergence of these new substances and our ability to understand and counteract their biological effects.

A primary area for advancement is in diagnostics. The development of rapid, broad-spectrum toxicological screening techniques is essential (Chatterton & Jones, 2013). Advanced analytical methods, such as high-resolution mass spectrometry, can help identify unknown compounds in clinical samples, moving a case from the "unknown" to the "known" category and allowing for more targeted treatment (Pichini et al., 2018). Concurrently, research is needed to elucidate the neurobiological mechanisms of NPS (Venkataraman et al., 2020). Preclinical studies using animal models are vital for characterizing the receptor binding profiles, neurotransmitter effects, and potential neurotoxicity of these emerging drugs (Sanchis‐Segura & Spanagel, 2006). This knowledge is crucial for predicting clinical syndromes and developing potential therapeutic countermeasures.

Another promising avenue is the identification of biomarkers that can assess the severity of intoxication and predict patient outcomes, regardless of the specific substance involved. For example, markers of neuroinflammation, neuronal injury, or specific patterns of metabolic dysregulation on advanced neuroimaging could provide objective measures of brain dysfunction (Crews & Vetreno, 2015). Understanding the common pathophysiological pathways, such as excitotoxicity, oxidative stress, and neuroinflammation, that are activated by a wide range of neurotoxic substances could lead to the development of broad-spectrum neuroprotective strategies (Virmani et al., 2010; Lehotský et al., 2009). These might include agents that mitigate glutamate-induced excitotoxicity or antioxidants that reduce cellular damage, offering a generalized approach to treating intoxication-induced encephalopathy (Virmani et al., 2010).

The principles of personalized medicine also hold promise. As our understanding of the genetic basis for drug metabolism and pharmacodynamic sensitivity grows, it may become possible to rapidly genotype patients in the emergency setting to identify those at high risk for severe toxicity due to factors like poor metabolizer status (Gram et al., 1993). This could guide dosing of supportive medications and raise the index of suspicion for prolonged or severe intoxication.

Finally, long-term follow-up studies of individuals who have experienced severe intoxication, particularly with NPS, are needed to understand the chronic neurological and psychiatric sequelae. While acute intoxication is defined as a transient state (Sarkar et al., 2023), the potential for lasting cognitive impairment, mood disorders, or psychosis as a consequence of a single severe toxic exposure is a significant concern that remains under-investigated (White et al., 1990; Carlin & O'Malley, 1996). Elucidating the mechanisms of long-term drug-induced neuroplasticity will be critical for developing rehabilitative and therapeutic strategies for these patients. The ultimate goal is to transform the management of unknown substance intoxication from a purely supportive and reactive discipline to one that is predictive, mechanism-based, and neuroprotective.

## Conclusion

Other (or Unknown) Substance Intoxication is a complex and often perilous clinical syndrome that represents a state of acute, reversible brain dysfunction (Sarkar et al., 2023; Schildkrout, 2014). While the specific etiological agent may be elusive, the resulting psychopathological phenomena manifest through a limited repertoire of neurobiological responses, representing a final common pathway of disrupted neural function (Kryzhanovskiĭ, 2002). The clinical presentation is fundamentally a substance-induced encephalopathy or delirium, characterized by disturbances in consciousness, cognition, perception, and behavior (Lipowski, 1987; Todd & Teale, 2017).

The biological underpinnings of this state are rooted in the profound disruption of the brain's delicate neurochemical equilibrium (Willner, 1984). The diverse clinical presentations, from deep coma to agitated psychosis, reflect the differential impact of intoxicating substances on major neurotransmitter systems, including the dopaminergic, serotonergic, GABAergic, and glutamatergic pathways (Ferner et al., 1995; Abou‐Donia, 2015). The recognition of specific toxidromes, such as serotonin syndrome or anticholinergic toxicity, provides a crucial framework for diagnosis and management even in the absence of a definitive toxicological identification (Scotton et al., 2019; Çiçek et al., 2022). These syndromes are not idiosyncratic but are predictable consequences of excessive pharmacological activity at specific receptor systems (Rahmani et al., 2011).

The integrity of key neural circuits—governing reward, executive function, emotion, and motor control—is temporarily compromised, leading to the characteristic behavioral and cognitive impairments of intoxication (Koob, 2013; Noël et al., 2010). An individual's response is further modulated by a host of factors, including genetic predispositions affecting drug metabolism and receptor sensitivity, as well as the neuroadaptive changes wrought by prior substance use and life stressors (Gram et al., 1993; Koob et al., 2015). Developmental stage is also a critical determinant of vulnerability, with the adolescent and elderly brain being particularly susceptible to severe toxic effects (Hyytiä, 2015; Francis, 1997).

Ultimately, the management of Other (or Unknown) Substance Intoxication relies on a foundational understanding of these biological principles. Supportive care remains the cornerstone, aimed at preserving vital functions while the brain and body clear the toxic agent (Sarkar et al., 2023; Rigaud et al., 2006). The judicious use of pharmacological interventions, from specific antagonists to agents that manage agitation or seizures, is guided by a clinical diagnosis of the underlying neuropharmacological state. As the landscape of substance use continues to evolve with the advent of novel psychoactive substances, a robust knowledge of the fundamental biological and neurological basis of intoxication will remain the most essential tool for clinicians navigating this challenging and critical area of medicine (Wojtyła-Buciora et al., 2023).


## References

1. Abdalá, L., & Arturo (2019). Abuso psicológico (AP).
2. Abdo, C. H. N. (2017). Sexualidade e doenças reumáticas. Revista Paulista de Reumatologia. https://doi.org/10.46833/reumatologiasp.2017.16.3.6-12
3. Abou‐Donia, M. B. (2015). Drugs of Abuse. https://doi.org/10.1002/9781118683484.ch26
4. Adam, N., Kandelman, S., Mantz, J., Chrétien, F., & Sharshar, T. (2013). Sepsis-induced brain dysfunction. Expert Review of Anti-infective Therapy. https://doi.org/10.1586/eri.12.159
5. Adams, B., & Bromley, B. (1998). Loss and grief therapy. https://doi.org/10.1007/978-1-349-26634-0_10
6. Adi, Y., Ashcroft, D. M., Browne, K. D., Beech, A. R., Fry-Smith, A., & Hyde, C. (2002). Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment. https://doi.org/10.3310/hta6280
7. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
8. Ait-El-Mkadem, S., Chaussenot, A., Bannwarth, S., Rouzier, C., & Paquis‐Flucklinger, V. (2015). CHCHD10-Related Disorders.
9. Ajayi, O., Esangbedo, A., Lawal, A. A., Olanrewaju, A. O., Ojo, T. O., & Talabi, O. (2023). Moral Injury, Trance and Possession State or a Schizophrenic Illness. a Case report. BJPsych Open. https://doi.org/10.1192/bjo.2023.359
10. Al-Balawi, T., Al-Greeshah, F., & Khan, S. (2003). Management of status epilepticus.. PubMed.
11. Alam, N., & Choudhary, K. (2023). Neurochemical Effects of Methylphenidate and Modafinil in Ameliorating Stress-Induced Cognitive Deficits. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.3c00077
12. Albalawi, R., Alsahli, H., Almutairi, N. B., & Alhashemi, M. (2024). Acute psychosis and behavioural changes with seizure-like hyperactive psychomotor activity secondary to isotretinoin initiation in a healthy young male: case report. Annals of Medicine and Surgery. https://doi.org/10.1097/ms9.0000000000001726
13. Alfonso‐Loeches, S., & Guerri, C. (2011). Molecular and behavioral aspects of the actions of alcohol on the adult and developing brain. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.3109/10408363.2011.580567
14. Altimier, L. (2008). Shaken Baby Syndrome. The Journal of Perinatal & Neonatal Nursing. https://doi.org/10.1097/01.jpn.0000311877.32614.69
15. Alvarez, C. M. (2016). Efectos de la estimulación multisensorial dentro de una sala oscura en el tratamiento del equilibrio en niños de 5 a 7 años con discapacidad intelectual.
16. AMIN, S. N., KHASHABA, A. S., Alazzam, A. Y., ALKHAWALDAH, H. M., ALBAKRI, K. A., Almajdoubah, O. A., ALABDALLAT, Y. J., & SEIF, A. S. A. (2023). Beyond cognition and sleep: Stop the domino effect. Journal of Experimental and Clinical Medicine. https://doi.org/10.52142/omujecm.40.1.28
17. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
18. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
19. Anani, S., Goldhaber, G., Wasserstrum, Y., Dagan, A., & Segal, G. (2018). The ‘SILENT Alarm’: When History Taking Reveals a Potentially Fatal Toxicity. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2018_000843
20. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
21. Andresen, M., & Andresen-Vasquez, M. (2016). A new instrument for assessing the experience of dying and death in the intensive care units from the perspective of relatives. Journal of Thoracic Disease. https://doi.org/10.21037/jtd.2016.06.07
22. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
23. Anisman, H. (2015). Drug Remedies to Attenuate Stress and Stress‐Related Disorders. https://doi.org/10.1002/9781118850350.ch21
24. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
25. Annoni, J., Staub, F., Bruggimann, L., Gramigna, S., & Bogousslavsky, J. (2006). Emotional Disturbances after Stroke. Clinical and Experimental Hypertension. https://doi.org/10.1080/10641960600549173
26. Ansari, I., Jabbar, Q., & Asim, S. A. (2018). Depression and its treatment - a mini review. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2018.09.00587
27. Antelo, M. J. G., Santos, H., Barbeito, Y. I., Silva, J. J. D., & Sobrido, M. J. (2012). Tratamiento de los trastornos de la marcha en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012532
28. Antoniuk, S. A. (2013). [Non-epileptic disorders in infancy and adolescence].. PubMed.
29. Araújo, R. C. B., Gomes, R. M., & Barbosa, M. U. F. (2017). A IMPORTÂNCIA DO BOBATH EM PACIENTES COM PARALISIA CEREBRAL.
30. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
31. Argyriou, A. A., Zolota, V., Kyriakopoulou, O., & Kalofonos, H. P. (2010). Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.. PubMed.
32. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
33. As, T. (2013). [Age-related aspects of depressive states].. PubMed.
34. Asakura, S. (2012). [Social anxiety disorder: current status and future directions].. PubMed.
35. Aubuchon, O., Huynh, L.-K., Dupont, D., Séguin, M., Beaudoin, C., Bernier, A., & Beauchamp, M. H. (2024). Optimal functioning after early mild traumatic brain injury: Evolution and predictors. Journal of the International Neuropsychological Society. https://doi.org/10.1017/s1355617724000572
36. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
37. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
38. Aydinak, S., Yalçın, C. Ö., & Abudayyak, M. (2018). Psychiatric Adverse Effects of Non-steroidal Analgesic Anti-inflammatory Drugs. Journal of Literature Pharmacy Sciences. https://doi.org/10.5336/pharmsci.2017-58076
39. Aydın, M., Deveci, U., & Orman, A. (2015). Neurotoxic Treatments in the Newborn Period. International Journal of Neurology Research. https://doi.org/10.17554/j.issn.2313-5611.2015.01.23
40. Bach, S. (2018). States of consciousness. Routledge eBooks. https://doi.org/10.4324/9780429471391-3
41. Badar, A. (2024). Serotonin syndrome: An often-neglected medical emergency. Journal of Family and Community Medicine. https://doi.org/10.4103/jfcm.jfcm_236_23
42. Bagri, K., Mehta, V., Singla, A., Deshmukh, R., & Singh, T. G. (2024). Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury. Apple Academic Press eBooks. https://doi.org/10.1201/9781032680026-10
43. Bakvis, P. (2005). Psychogenic non epileptic seizures : towards an integration of psychogenic, cognitive and neurobiological aspects.
44. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
45. Balvir, K. S., Dhanvij, B., Telrandhe, S., & Wajgi, R. D. (2021). A Case Report on Management of Subdural Hematoma. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
46. Bansal, V., Ruland, S., & Aiyagari, V. (2014). DISORDERS OF CONSCIOUSNESS. CRC Press eBooks. https://doi.org/10.1201/b16337-7
47. Baran, A. S. (2003). Sleep Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.028
48. Barkin, R. L. (2007). Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31804c7292
49. Barnes, T. R. E., & Paton, C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. https://doi.org/10.1136/bmj.d3371
50. Barolin, G. S. (1998). Rehabilitation hospitalism. International Journal of Rehabilitation Research. https://doi.org/10.1097/00004356-199806000-00008
51. Barry, S., Baird, G., Lascelles, K., Bunton, P., & Hedderly, T. (2011). Neurodevelopmental movement disorders - an update on childhood motor stereotypies. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.04058.x
52. Bartolomeo, P., & Migliaccio, R. (2016). Disorders of attentional processes. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0015
53. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
54. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
55. Batyukina, C. V., Ebzeeva, E. Y., & Shatalova, N. A. (2020). Medications associated with development of drug-induced depression. Medical alphabet. https://doi.org/10.33667/2078-5631-2020-11-36-45
56. Baxter, P. (2015). States of consciousness: new insights and further questions. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.12666
57. Becerril‐Villanueva, E., Gutiérrez, M. E. H., Camacho, I. G., García, L. Á., Pérez‐Tapia, S. M., & Romero, L. P. (2012). Los efectos conductuales modulados por las citocinas. Salud Mental.
58. Becker, H. C. (1998). Kindling in alcohol withdrawal.. PubMed.
59. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
60. Becker, M. A., Weinberger, T. E., & Ocker, L. J. (2022). Mood Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003099062-21
61. Becker, S. P., & Barkley, R. A. (2018). Sluggish cognitive tempo. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198739258.003.0015
62. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
63. Beh, P., & Foo, T. K. (2023). Self-Neglect. CRC Press eBooks. https://doi.org/10.1201/9781003138754-55
64. Bell, C. M. (2009). L. https://doi.org/10.1093/oso/9780195341591.003.0012
65. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
66. Belli, H., Akbudak, M., Ural, C., & Kulacaoğlu, F. (2012). Solitary lesion in ponto-mesencephalic area related secondary mania: a case report.. PubMed.
67. Bengtsson, B.-O. (1992). On the hypersensitivity syndrome induced by the selective serotonin reuptake inhibiting antidepressant Zimeldine : A clinical and experimental study.
68. Beni, F. (2019). Addiction and Trauma Re-examined through the lens of Complexity Theory. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2019.13.555853
69. Beninger, R. J. (2018). Life's rewards. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198824091.001.0001
70. Bereda, G. (2022). Stage and symptoms of bipolar disorders. Insights on the Depression and Anxiety. https://doi.org/10.29328/journal.ida.1001030
71. Berg, A. T. (2011). Epilepsy, cognition, and behavior: The clinical picture. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02905.x
72. Bernardo, A. P. M. (2003). O delírio em cuidados paliativos. Revista Portuguesa de Medicina Geral e Familiar. https://doi.org/10.32385/rpmgf.v19i1.9904
73. Bilge, S. (2022). Neurotoxicity, Types, Clinical Manifestations, Diagnosis and Treatment. IntechOpen eBooks. https://doi.org/10.5772/intechopen.101737
74. Billiard, M., & Carlander, B. (2003). Other hypersomnias. SLEEP. https://doi.org/10.1007/978-1-4615-0217-3_34
75. Bithal, P. K., & Chavali, S. (2021). Paroxysmal Sympathetic Hyperactivity: Ignoring the Presence of an Elephant in the Room. Journal of Neuroanaesthesiology and Critical Care. https://doi.org/10.1055/s-0041-1740206
76. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
77. Blackburn, L. B., Zelko, F., & Shurtleff, H. A. (2001). Seizure disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545894.008
78. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
79. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
80. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
81. Boggs, J. (2002). Seizures and Organ Failure. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_5
82. Bokor, G., & Anderson, P. (2014). Ketamine. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014525754
83. Bonnet, M. H., & Arand, D. L. (2008). Chronic insomnia. CRC Press eBooks. https://doi.org/10.3109/9780203091715-12
84. Bonnet, M. H., & Arand, D. L. (2013). Insomnia. https://doi.org/10.3920/9789086867639_003
85. Borsook, D., Aasted, C. M., Burstein, R., & Becerra, L. (2013). Migraine Mistakes. The Neuroscientist. https://doi.org/10.1177/1073858413503711
86. Bostankolu, G., Ayhan, Y., Çetin, F. Ç., & Yazıcı, M. K. (2014). Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125314561467
87. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
88. Bouras, G., & Lazaratou, E. (2012). [Emergence of early childhood trauma in adult psychiatric symptomatology].. PubMed.
89. Bourin, M., David, D. J., & Dhonnchadha, B. À. N. (2002). Sedation: a non-specific phenomenon -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
90. Braddon, J., & Phillips, P. (1999). Dangerous drugs in endocrinology. Current therapeutics.
91. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
92. Brady, K. T., & Sinha, R. (2005). Co-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic Stress. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.162.8.1483
93. Brady, K. T., & Sinha, R. (2007). Co-Occurring Mental and Substance Use Disorders: The Neurobiological Effects of Chronic Stress. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/foc.5.2.foc229
94. Bragazzi, N. L., Khabbache, H., Perduca, M., Neri, B., Firenzuoli, F., Penazzi, G., Simíμes, M., Zerbetto, R., & Re, T. S. (2018). Parapsychology, N,N-Dimethyltryptamine and the Pineal Gland. Cosmos and history.
95. Braksick, S. A., & Wijdicks, E. F. M. (2019). Neurogenic Cardiac Manifestations. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0017
96. Brang, D. (2010). Synesthesia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0971
97. Breggin, P. R. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk & Safety in Medicine. https://doi.org/10.3233/jrs-1999-177
98. Brignole, M., Alboni, P., Benditt, D. G., Bergfeldt, L., Blanc, J., Thomsen, P. E. B., Dijk, J. G. V., Fitzpatrick, A., Hohnloser, S. H., Janousek, J., Kapoor, W. N., Kenny, R. A., Kułakowski, P., Masotti, G., Moyá, A., Raviele, A., Sutton, R., Theodorakis, G., Ungar, A., & Wieling, W. (2004). Guidelines on Management (diagnosis and treatment) of syncope ? update 2004. EP Europace. https://doi.org/10.1016/j.eupc.2004.08.008
99. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
100. Brody, D. L. (2019). Return to Driving. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0028
101. Brogaard, B. (2013). Serotonergic Hyperactivity as a Potential Factor in Developmental, Acquired and Drug-Induced Synesthesia. Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2013.00657
102. Brown, R. (2019). Biopharmacologic and Neurophysiologic Basis of Addiction. Pain. https://doi.org/10.1007/978-3-319-99124-5_240
103. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
104. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
105. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
106. Brüne, M. (2008). Dementia. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199207688.003.0009
107. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
108. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
109. Buckley, T. M., & Guilleminault, C. (2008). Index. CRC Press eBooks. https://doi.org/10.3109/9781420019926-54
110. Budak, E. (2015). Alkol ve Madde Etkisi Altinda Araç Kullanimi ile İlişkili Psikolojik Faktörler Driving under the Influence of Alcohol and Substance and Related Psychological Factors.
111. Budak, E., & Taymur, İ. (2015). Psychological Factors related with Driving under the Influence of Alcohol and Substance Use. DergiPark (Istanbul University). https://doi.org/10.18863/pskguncel.133504
112. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
113. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
114. Butterworth, R. F. (1995). The Role of Liver Disease in Alcohol-Induced Cognitive Defects.. PubMed.
115. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Post-Stroke Apathy: An Exploratory Longitudinal Study. Cerebrovascular Diseases. https://doi.org/10.1159/000350202
116. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Supplementary Material for: Post-Stroke Apathy: An Exploratory Longitudinal Study. Figshare. https://doi.org/10.6084/m9.figshare.5124829
117. Calvani, M., Anania, C., Cuomo, B., D’Auria, E., Decimo, F., Indirli, G. C., Mastrorilli, V., Santoro, A., Sartorio, M. U. A., & Veronelli, E. (2020). Summation anaphylaxis: A challenging diagnosis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13347
118. Campoy, A. T., Rotger, M. Y., Gutiérrez, L. R. D. L. H., & Pastorelli, R. V. (2011). ¿Psicosis mental injertada o retraso mental? A propósito de un caso.. Psiquiatria.com.
119. Canapathy, M., Kurushev, J., Chitra, F., & Dash, M. (2019). Impact of Sensory Deprivation on Health Outcome. Acta Scientific Paediatrics. https://doi.org/10.31080/aspe.2019.02.0165
120. Candura, S. M., & Scelsi, R. (2013). [Occupational toxic neuropathies: morphology in peripheral nerve biopsies].. PubMed.
121. Cano‐Vindel, A., Miguel-Tobal, J. J., González, H. M., & Díez, I. I. (1994). El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología.
122. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
123. Caraiane, A., Szalontay, A. S., Macovei, L. A., Romila, A., Indrei, L. L., Decusară, M., & Tarc, T. (2018). Oral-Facial Manifestations Caused by the Use of Psychotropic Medication in Psychiatric Patients. Revista de Chimie. https://doi.org/10.37358/rc.18.6.6374
124. Carlin, A., & O'Malley, S. (1996). Neuropsychological Consequences of Drug Abuse. https://doi.org/10.1093/oso/9780195090734.003.0019
125. Carota, A., Diéguez, S., & Bogousslavsky, J. (2005). Psychopathologie des accidents vasculaires cérébraux. Gériatrie et Psychologie Neuropsychiatrie du Viellissement.
126. Carota, A., Diéguez, S., & Bogousslavsky, J. (2005). Psychopathology of stroke. Gériatrie et Psychologie Neuropsychiatrie du Viellissement.
127. Carp, K. C., & Donatelli, R. (2024). Evidence-Based Rehabilitation of Concussion or Mild Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9781003524212-24
128. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
129. Ceravolo, F., Sestito, S., Falvo, F., Salpietro, V., Polizzi, A., Ruggieri, M., Bruno, M., & Concolino, D. (2016). Neurological Involvement in Inherited Metabolic Diseases: An Overview. Journal of Pediatric Biochemistry. https://doi.org/10.1055/s-0036-1582235
130. Chaki, S., & Okuyama, S. (2006). [Neuropeptide receptors: novel therapeutic targets for depression].. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.127.196
131. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
132. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
133. Charante, E. P. M. V., Richard, E., & Perry, M. (2022). [Forgetfulness].. PubMed.
134. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
135. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
136. Chicoș, O., Perri, D., Capriș, L., Iliescu, A. I. B., & Kantor, C. (2019). Social-Cultural Influences and Personality Disorders Favoring Drug Consumption. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s1/3
137. Ching, S., Westover, M. B., Shafi, M., Cash, S. S., & Brown, E. N. (2015). Real-time segmentation and tracking of brain metabolic state in ICU EEG recordings of burst suppression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139941433.015
138. Choi, W., & Young, M. J. (2023). Disambiguating Consciousness in Clinical Settings. Neurology. https://doi.org/10.1212/wnl.0000000000207765
139. Choi‐Kwon, S., & Kim, J. S. (2022). Anger, a Result and Cause of Stroke: A Narrative Review. Journal of Stroke. https://doi.org/10.5853/jos.2022.02516
140. Chou, R., Norris, S. L., Carson, S., & Chan, B. (2007). Drug Class Review: Drugs for Neuropathic Pain: Final Report [Internet].
141. Chouinard, G., & Chouinard, V. (2015). New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000371865
142. Chu, B., Marwaha, K., Sanvictores, T., & Ayers, D. (2019). Physiology, Stress Reaction. StatPearls.
143. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
144. Chung, S., Oh, K., Cho, K., & Hwang, I.-K. (2003). Antidepressant-Induced Somnambulism：A Case of Mirtazapine. Sleep Medicine and Psychophysiology.
145. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
146. Ciraulo, D. M., & Ciraulo, D. A. (2008). Benzodiazepines <i>Misuse, Abuse, and Dependence</i>. https://doi.org/10.1093/oso/9780195300550.003.0019
147. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Consciousness disorders: vegetative state and minimally conscious state].. PubMed.
148. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Rare consciousness disturbances in toxicological practice: akinetic mutism, somnambulism, locked-in syndrome, and psychogenic coma].. PubMed.
149. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
150. Clark, J. D., Rager, D. R., & Calpin, J. P. (1997). Animal well-being. II. Stress and distress.. PubMed.
151. Clark, J. D., Rager, D. R., & Calpin, J. P. (1997). Animal well-being. III. An overview of assessment.. PubMed.
152. Coelho, A. A., Lima-Bastos, S., Gobira, P. H., & Lisboa, S. F. (2023). Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders. Neuronal Signaling. https://doi.org/10.1042/ns20220034
153. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
154. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
155. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
156. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
157. Constantinescu, C. S., & Lim, S. (2018). Weakness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199568741.003.0044
158. Cook, B. A., & Spence, A. (1997). Post-operative central anticholinergic syndrome. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199701000-00001
159. Copeland‐Linder, N., Onigu-Otite, E., Serico, J. M., Jamora, M., & Belcher, H. M. E. (2017). Neurobiology of Child Maltreatment and Psychological Trauma. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199937837.003.0181
160. Cortés, V. A. L. (2018). Características neuropsicológicas de pacientes con enfermedad de Parkinson sin demencia. https://doi.org/10.14201/gredos.139596
161. Costantino, C., Marcato, A., Donetti, C., Marangio, E., & Saccavini, M. (2008). Informare ed educare in ospedale per prevenire il rischio cadute nell'anziano.
162. Costanzo, R. M., DiNardo, L. J., Reiter, E. R., & Doty, R. L. (2003). Head Injury and Taste. CRC Press eBooks. https://doi.org/10.1201/9780203911457-50
163. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
164. Cowl, A. (2015). Terminal Decline. The Encyclopedia of Adulthood and Aging. https://doi.org/10.1002/9781118521373.wbeaa326
165. Cox, J. M. (2009). Advice and information on tuberous sclerosis complex. British Journal of Neuroscience Nursing. https://doi.org/10.12968/bjnn.2009.5.4.41686
166. Crews, F. T., & Vetreno, R. P. (2015). Mechanisms of neuroimmune gene induction in alcoholism. Psychopharmacology. https://doi.org/10.1007/s00213-015-3906-1
167. Crichton, R. R., & Ward, R. J. (2013). Ageing and Mild Cognitive Impairment (MCI). https://doi.org/10.1002/9781118553480.ch05
168. Crichton, R. R., & Ward, R. J. (2013). Alcoholic Brain Damage. https://doi.org/10.1002/9781118553480.ch12
169. Cruz, S. L., & López, C. B. (2003). Fármacos que producen dependencia física y adicción. Avance y perspectiva.
170. Cruz, V. E. R., Palacios, L. P. T., Adriano, M. P. C., Lozada, E. M. V., Quingatuña, D. E. E., Reyes, E. P. B., Sailema, P. I. Y., Inca, J. I. S., & Ruiz, G. B. F. (2020). Avances en el manejo del delirium en los pacientes geriátricos. AVFT – Archivos Venezolanos de Farmacología y Terapéutica. https://doi.org/10.5281/zenodo.4058882
171. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
172. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
173. Curto, M. P. M., & Quintana, M. V. M. (2009). [Co-morbility during depression].. PubMed.
174. Czajkowska‐Malinowska, M., & Cofta, S. (2014). Obturacyjny bezdech senny i jego społeczne następstwa.
175. Cáceres, F., Baca, G. H. R., Osorto, L. J. R., Godoy, K. J. Á., Hernández, G. R. O., Barahona, R. D. S., Sorto, N. D. Z., Suárez, M., Anduray, A. S. M., Mendoza, K. V. J., & Vargas, G. H. R. (2024). Síndrome Convulsivo. Religación Press eBooks. https://doi.org/10.46652/religacionpress.195.c296
176. Cüreoǧlu, S., FUKUSHIMA, H., Schachern, P. A., Paparella, M. M., & HARADA, T. (2005). The Effects of Type 2 Diabetes Mellitus on the Cochlear Structure in Human Temporal Bones. Otolaryngology. https://doi.org/10.1016/j.otohns.2005.05.545
177. Dada, M. U., Oluwole, M., Obadeji, A., & Ajayi, O. (2011). Dexamethasone induced psychosis presenting with catatonic features. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v14i4.10
178. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
179. Daley, D. C., & Douaihy, A. (2019). Psychiatric Illness Co-occurring with a Substance Use Problem. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0008
180. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
181. Daley, D. C., & Douaihy, A. (2019). Understanding Substance Use Problems. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0002
182. Dalvi, A., Lyons, K. E., & Pahwa, R. (2006). Secondary Dystonia. CRC Press eBooks. https://doi.org/10.3109/9781420019988-19
183. Dargone, M.-A., Conso, F., Asselain, D., & Choudat, D. (2010). L'intolérance environnementale idiopathique (sensibilité chimique multiple). Environnement Risques & Sante. https://doi.org/10.1684/ers.2010.0381
184. Darwish, H. (1980). Promethazine-Induced Acute Dystonic Reactions. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1980.02130220066020
185. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
186. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
187. DeJong, R. N. (1969). Memory Loss due to Hippocampal Lesions. Archives of Neurology. https://doi.org/10.1001/archneur.1969.00480100015001
188. Delgado‐Losada, M. L., Aizcorbe, J. R. R., & Guinea, S. F. (2001). Aspectos de la Neuropsicología Forense en el envejecimiento y en las demencias. Revista de Neurología. https://doi.org/10.33588/rn.3208.2000187
189. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
190. Devinsky, O., & D’Esposito, M. (2003). Attention and Attentional Disorders. https://doi.org/10.1093/oso/9780195137644.003.0004
191. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
192. Dimitrijević, M., Kakulas, B. A., McKay, W., & Vrbovà, G. (2011). Restorative Neurology of Spinal Cord Injury. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199746507.001.0001
193. Diniari, N. K. S., & Hanati, N. (2012). POSSESSION, REVIEW FROM CULTURAL AND PSYCHIATRY. Medicina-buenos Aires.
194. Divya, M., Preeti, B., & Srihari, S. (2023). EVALUATION OF DHARANIYA VEGA (SUPPRESSIBLE URGES) BY DEVELOPING TOOLS OF ASSESSMENT W.S.R.TO MANODAIHIKA SIDDHANT (PSYCHOSOMATIC CONCEPT) AND ROLE OF SATTVAVAJAY CHIKITSAA IN SUPPRESSION OF DHARANIYA VEGA -A CLINICAL AND ASSESSMENT PROTOCOL. PARIPEX-INDIAN JOURNAL OF RESEARCH. https://doi.org/10.36106/paripex/2510301
195. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
196. Douglas, M. E., Kim, B., Mayer, G., Crosby, B., & Towe-Goodm, N. (2012). Maternal Depression, Mothering and Child Development. InTech eBooks. https://doi.org/10.5772/38048
197. Dremencov, E., Maslennikova, E., Ishmatova, A., Downey, H. F., Klebanov, I. R., Tseilikman, O. B., Komelkova, M., Lapshin, M., Vasilyeva, M. V., Bornstein, S. R., Perry, S. W., Wong, M., Licinio, J., Yehuda, R., & Ullmann, E. (2019). Post-Traumatic Stress Disorder Chronification via Monoaminooxidase and Cortisol Metabolism. Hormone and Metabolic Research. https://doi.org/10.1055/a-0975-9268
198. Dreyer-Oren, S. E., Mitnaul, L., & Holtzheimer, P. E. (2018). Mood Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy25
199. Drinkhill, M. J., Rivera, M. C., & Hainsworth, R. (2013). Autonomic function at high altitudes. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198566342.003.0017
200. Dube, S., & Babar, A. (2023). Stress and Insomnia – A Vicious Circle. Sustainability Agri Food and Environmental Research. https://doi.org/10.7770/safer-v13n2-art742
201. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
202. Duits, N., & Bos, F. M. (1993). [Psychiatric disorders with use of simvastatin].. PubMed.
203. durantez, E. R. (2006). Neurobiología de la adicción a las sustancias de abuso. DOAJ (DOAJ: Directory of Open Access Journals).
204. Durán, L. V. B., González, M., & Álvarez, G. B. (2020). Trastorno por estrés postrauma. Revista Medica Sinergia. https://doi.org/10.31434/rms.v5i9.568
205. Díaz, M. F. G., & Pérez, L. R. (2019). Factores que intervienen en la depresión de personas con enfermedad renal crónica en tratamiento de hemodiálisis en una población mexiquense.
206. Dünser, M. W., & Hasibeder, W. (2009). Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress. Journal of Intensive Care Medicine. https://doi.org/10.1177/0885066609340519
207. D’Souza, R. S., & Hooten, W. M. (2019). Somatic Syndrome Disorders.
208. Ebenezer, I. S. (2015). Drug Abuse and Addiction. https://doi.org/10.1002/9781118385777.ch11
209. Ebenezer, I. S. (2015). Sleep and Sleep Disorders. https://doi.org/10.1002/9781118385777.ch9
210. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
211. Engelmann, C. M., & Siert, L. (2007). [Cognitive disturbances following severe traumatic brain injury].. PubMed.
212. Ereshefsky, L., Tran-Johnson, T., & Watanabe, M. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.. PubMed.
213. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
214. et.al., J. F. L. (2002). Neurobiology of tic disorders, including Tourette’s syndrome. https://doi.org/10.1093/oso/9780195141733.003.0013
215. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
216. Fariba, K. (2021). Case Presentation: Iatrogenic Psychosis. https://doi.org/10.53902/jpssr.2021.01.000522
217. Farinaz, N., Nik, E. R., & Sadeghi, M. (2011). Concentration-Effect Relationship of Intrapritoneal Administration of 1, 25 (OH) 2-Vitamin D in a Chronic Constriction Model of Neuropathic Pain.
218. Farne, H., Norris-Cervetto, E., & Warbrick‐Smith, J. (2015). Blackout. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198716228.003.0009
219. Fatma, S., Sunarti, S., Mardhiyah, F., Wirabhatari, A., & Winstonly, B. (2024). Tantangan Dalam Penilaian Klinis Gejala Depresi pada Usia Lanjut. Jurnal Klinik dan Riset Kesehatan. https://doi.org/10.11594/jk-risk.03.2.6
220. Fava, G. A., & Cosci, F. (2019). Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19com12794
221. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
222. Fernandez, H. H., & Simuni, T. (2007). Anxiety. Humana Press eBooks. https://doi.org/10.1385/1-59259-859-5:13
223. Ferrara, P. (2014). Child abuse and neglect: psychiatric and neuro-biological consequences. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a32
224. Ferrari, M., Silva, J. A., Leong, G., & Weinstock, R. (1997). The Role of Mania in the Genesis of Dangerous Delusional Misidentification. Journal of Forensic Sciences. https://doi.org/10.1520/jfs14179j
225. Ferri, C., Caletti, M. T., & Provini, F. (2017). NREM and other parasomnias. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199682003.003.0039
226. Fink, G. (2015). Posttraumatic Stress Disorder: Introduction to Special Issue. Journal of Trauma & Treatment. https://doi.org/10.4172/2167-1222.s4-009
227. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
228. Fink, M. (2010). Other Uses: Psychosis, Pregnancy, and Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0012
229. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
230. Fontalba-Navas, A., & Caparros-del-Moral, I. (2015). New Approaches to Psychotic Agitation: Staccato Loxapine. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30809-9
231. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
232. Forcén, F. E. (2015). Akathisia: Is Restlessness a Primary Condition or an Adverse Drug Effect? Keep a Discerning Eye out for This Adverse Effect of Antipsychotics and Other Drugs. Current psychiatry.
233. Forrest, J., Willis, L., Holm, K., Kwon, M. S., Anderson, M. A., & Foreman, M. D. (2007). Recognizing quiet delirium.. PubMed. https://doi.org/10.1097/01.naj.0000265267.77070.0c
234. Forsyth, R., & Newton, R. (2017). Signs and symptoms. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198784449.003.0003
235. Fountoulakis, K. Ν., Andreoulakis, E., & Iacovides, A. (2013). Nonsensory Hallucinations or Obsessive Symptoms?. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/nmd.0b013e3182a21864
236. Foyet, H. S., Balmuș, I.-M., Hervé, N. A. H., Emmanuel, A., Guenné, S., Kiendrébéogo, M., & Ciobîcă, A. (2017). Ethnopharmacological approaches in mood and anxiety disorders. The relevance of the oxidative stress status. Journal of Complementary and Integrative Medicine. https://doi.org/10.1515/jcim-2016-0059
237. Francis, J. (1997). Delirium. Geriatric medicine. https://doi.org/10.1007/978-1-4757-2705-0_60
238. Franjić, S. (2022). Pain Is An Uncomfortable Sensation. Journal of Adolescent and Addiction Research. https://doi.org/10.58489/2836-2314/001
239. Franjić, S. (2023). Post-Traumatic Stress Disorder Appears as a Traumatic Experience. https://doi.org/10.61440/jcpn.2023.v1.04
240. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
241. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
242. Franz, M. R., & Schepank, H. (1997). [Mood disorders. Prevalence and course of unspecified functional disorders from the epidemiologic and psychosomatic viewpoint].. PubMed.
243. Freitas, C., Mendes, A. M., & Queirós, S. (2016). The role of modified states of consciousness in drug use. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1012
244. Fries, W. (2013). Verhaltensstörungen nach Frontalhirnschädigung. neuroreha. https://doi.org/10.1055/s-0033-1347961
245. Fuente, V. D. L., Estivill, E., & Barraquer, A. (1997). [Pharmacological treatment of insomnia in children with neurological disorders].. PubMed.
246. Fugate, J. E. (2019). Consequences of Anoxia and Ischemia to the Brain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0011
247. Gallego, D., Figueroa, J., & Orozco, C. (2010). Síndrome de disfunción cognitiva de perros geriátrico. Revista Mvz Córdoba. https://doi.org/10.21897/rmvz.313
248. Gallino, G., & Liffredo, C. (1993). [Inappropriate drug use in elderly patients. Considerations on various psychologic aspects].. PubMed.
249. Gallo, J. J., & Rabins, P. V. (1999). Depression without sadness: alternative presentations of depression in late life.. PubMed.
250. Gaona, P., & Shirley, C. (2017). Proceso de atención de enfermería a pacientes con ansiedad relacionada a la abstinencia por alcohol según criterio de diagnostico nanda-nic-noc..
251. Garcia, P. A. G., & Martinez, A. C. L. (2019). Síndrome de alienación parental: consecuencias en los hijos a nivel psicológico..
252. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
253. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
254. George, O., & Koob, G. F. (2017). Individual differences in the neuropsychopathology of addiction. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.3/gkoob
255. Gerlach, M., Mehler‐Wex, C., & Schimmelmann, B. G. (2014). Antipsychotics. https://doi.org/10.1007/978-3-7091-1501-5_5
256. Ghaemi, S. N. (2018). Children. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0028
257. Ghogare, A. S., Patil, P. S., & Vankar, G. K. (2021). A Systematic Review of Childhood Psychological Traumas and Alexithymia Among Persons with Alcohol Dependence Syndrome. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_54_21
258. Ghosh, S., Singha, P. S., & Ghosh, D. (2023). Neuroprotective compounds from three common medicinal plants of West Bengal, India: a mini review. Exploration of neuroscience. https://doi.org/10.37349/en.2023.00030
259. Gi, S. (2011). [Neurophysiological and neurotransmitter mechanisms of behavior inhibition in normal and pathological conditions]..
260. Giannuzzi, R., Testa, A. C., Sollazzo, F., Petrongolo, L., Bernardini, L., & Daini, S. (2013). Psychiatric emergencies (part I): psychiatric disorders causing organic symptoms.. PubMed.
261. Glassford, J. A. G. (2017). The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Frontiers in Physiology. https://doi.org/10.3389/fphys.2017.00088
262. Gn, K. (2002). [The general theory of pathophysiological mechanisms of neurological and psychopathological syndromes].. PubMed.
263. Gobeske, K. T., & Wijdicks, E. F. M. (2019). Serotonin Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0075
264. Goldberg, J. F., Singer, T. M., & Garno, J. L. (2001). Suicidality and substance abuse in affective disorders.. PubMed.
265. Goldman, J. G., & Galicia, C. M. G. (2022). Movement Disorders Associated With SSRIs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0007
266. Goldstein, A. (2001). The Seesaw Brain: "Highs" and Adaptations. Addiction. https://doi.org/10.1093/oso/9780195146639.003.0006
267. Goldstein, D. S. (2002). Dysautonomias: Clinical Disorders of the Autonomic Nervous System. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-9-200211050-00011
268. Good, M. I. (1989). Substance-Induced Dissociative Disorders and Psychiatric Nosology. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198904000-00003
269. Goodman, J., McIntyre, C. K., & Packard, M. G. (2017). Amygdala and Emotional Modulation of Multiple Memory Systems. InTech eBooks. https://doi.org/10.5772/intechopen.69109
270. Goran, G. V. (2022). Diagnosis and therapy of neurotoxicological syndromes in animals Suggested citation for this article: Goran GV. Diagnosis and therapy of neurotoxicological syndromes in animals. Practica Veterinară.ro. 2022;36(2):12-21. Practica Veterinara ro. https://doi.org/10.26416/pv.36.2.2022.6431
271. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
272. Gordon, M. F., Hauser, R. A., Barkay, H., Fernandez, H. H., Factor, S. A., Jimenez‐Shahed, J., Gross, N. J., Marinelli, L., Wilhelm, A., Savola, J., & Anderson, K. E. (2022). Effects of Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders (P9-11.002). Neurology. https://doi.org/10.1212/wnl.98.18_supplement.1791
273. Goyal, A., Pallavi, K., & Awasthy, A. K. (2023). Reemergence of Neurological Deficit with Hyponatremia—When Obvious Is Not True. Journal of Neuroanaesthesiology and Critical Care. https://doi.org/10.1055/s-0042-1758459
274. Grajales, D. V. (2019). La posesión demoníaca: psicosis, neurosis histérica o trastorno neuropsicológico. Poiésis. https://doi.org/10.21501/16920945.3198
275. Gram, L. F., Brøsen, K., Sindrup, S. H., & Skjelbo, E. (1993). Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. Nordic Journal of Psychiatry. https://doi.org/10.3109/08039489309102787
276. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
277. Grant, J. E., Schreiber, L. R., & Odlaug, B. L. (2013). Phenomenology and Treatment of Behavioural Addictions. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371305800502
278. Greenson, R. R. (2018). Acting Out. Routledge eBooks. https://doi.org/10.4324/9780429483424-13
279. Griswold, K., Regno, P. A. D., & Berger, R. C. (2015). Recognition and Differential Diagnosis of Psychosis in Primary Care.. PubMed.
280. Grosso, S., Cioni, M., Pucci, L., Morgese, G., & Balestri, P. (1999). Selective mutism, speech delay, dysmorphisms, and deletion of the short arm of chromosome 18: a distinct entity?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.67.6.830
281. Grover, S., Sarkar, S., & Avasthi, A. (2022). Management of Systemic Medical Emergencies Associated with Psychotropic Medications. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_1014_21
282. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
283. Guerrini, R., & Falchi, M. (2011). Dravet syndrome and <i>SCN1A</i> gene mutation related‐epilepsies: cognitive impairment and its determinants. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.03966.x
284. Gupta, K., & Mamidi, P. (2022). Madonmada of Bhela samhita. Journal of Applied Consciousness Studies. https://doi.org/10.4103/ijoyppp.ijoyppp_16_21
285. Gupta, T., Bhagat, S., & Gupta, S. (2005). INSOMNIA- AN INCREASING TREND IN PRESENT ERA. World Journal of Pharmaceutical and life sciences.
286. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
287. Haddad, P., & Dursun, S. (2007). Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.918
288. Hadi, I., Wijayati, F., Usman, R. D., & Rosyanti, L. (2017). Major Depressive Disorder: A Mini Review. Health Information Jurnal Penelitian. https://doi.org/10.36990/hijp.v9i1.102
289. Hainline, B., Gurin, L., & Torres, D. M. (2019). Anxiety Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0016
290. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
291. Hainline, B., Gurin, L., & Torres, D. M. (2019). Unmasking Neuropsychiatric Disorders Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0035
292. Hajj, G. N. M., Tiago, G., Casini, M., & Marilene, H. (2012). Transmissible Spongiform Encephalopathies. InTech eBooks. https://doi.org/10.5772/29586
293. Halbauer, J. D., Ashford, J. W., Zeitzer, J. M., Adamson, M. M., Lew, H. L., & Yesavage, J. A. (2009). Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. The Journal of Rehabilitation Research and Development. https://doi.org/10.1682/jrrd.2008.08.0119
294. Hamed, S. A. (2018). Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2019.1555468
295. Hantson, P. (2004). Convulsions d'origine toxique. Réanimation. https://doi.org/10.1016/j.reaurg.2004.03.015
296. Hantson, P. (2013). Conduite à tenir devant les encéphalopathies et les comas toxiques. Références en réanimation. https://doi.org/10.1007/978-2-8178-0301-2_5
297. Hashimoto, K. (2019). Non-attendance at School of Children with Neurocognitive Disorder after Brain Injury. The Japanese Journal of Rehabilitation Medicine. https://doi.org/10.2490/jjrmc.56.463
298. Haslam, R. H. A. (1997). Nonfebrile Seizures. Pediatrics in Review. https://doi.org/10.1542/pir.18.2.39
299. Hayes, A., & Lingford‐Hughes, A. (2023). Drug Use, Addiction, Tolerance, Withdrawal and Relapse. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.058
300. Haywood, P., Divekar, N., & Karalliedde, L. (1999). Concurrent medication and the neuromuscular junction. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199902000-00002
301. Heffernan, S. P., Oh, E. S., Lyketsos, C. G., & Neufeld, K. J. (2014). Delirium. https://doi.org/10.1002/9781118799574.ch14
302. Heilbroner, P. L., & Castaneda, G. Y. (2007). Pediatric neurology : essentials for general practice. Lippincott Williams & Wilkins eBooks.
303. Heilman, K. M., Blonder, L. X., Bowers, D., & Valenstein, E. (2003). Emotional Disorders Associated with Neurological Diseases. https://doi.org/10.1093/oso/9780195133677.003.0016
304. Heilman, K. M., Watson, R. T., & Valenstein, E. (2003). Neglect and Related Disorders. https://doi.org/10.1093/oso/9780195133677.003.0013
305. Heinz, A. (2017). Learning Mechanisms in Addictive Disorders. The MIT Press eBooks. https://doi.org/10.7551/mitpress/9780262036894.003.0008
306. Henn, F. A., Edwards, E., Anderson, D. W., & Vollmayr, B. (2002). Psychotherapy and antidepressant treatment of depression: evidence for similar neurobiological mechanisms.. World Psychiatry.
307. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
308. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Polibea.
309. Herreras, E. B., & Gutiérrez, G. M. (2008). Adicciones y funcionamiento ejecutivo. Psicología y Psicopedagogía.
310. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
311. Hj, L., & Möller-Nehring, E. (1997). [Is the anxiety about Ecstasy justified?].. PubMed.
312. Hm, M., Mj, V. D. B., & Cj, V. (1998). [Immunology in medical practice. XIV. Central nervous system complications in systemic autoimmune diseases].. PubMed.
313. Hocker, S. E. (2015). Intoxications and Nontraumatic Neurologic Injury. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0093
314. Hoffmann, G., Adler, L., Hajak, G., Lehmann, K. A., Kunert, H., Issinger, J., Böke, J., Huether, G., & Rüther, E. (1997). On the Problems of Switching from Intravenous to Oral Administration in Drug Treatment of Endogenous Depression. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-979484
315. Holgate, S. T. (2002). Considerations on third generation antihistamines. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01339.x
316. Hollon, S. D., Stewart, M. O., & Strunk, D. R. (2005). Enduring Effects for Cognitive Behavior Therapy in the Treatment of Depression and Anxiety. Annual Review of Psychology. https://doi.org/10.1146/annurev.psych.57.102904.190044
317. Holtzheimer, P. E., & Hamani, C. (2014). Deep brain stimulation for treatment-resistant depression. https://doi.org/10.2217/ebo.13.577
318. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
319. Hong, C. (2013). 조현병 스펙트럼 및 기타 정신병적 장애, 성격장애. 한국심리학회 학술대회 자료집.
320. Horiguchi, T. (2017). Intermittent Explosive Disorder. The SAGE Encyclopedia of Abnormal and Clinical Psychology. https://doi.org/10.4135/9781483365817.n749
321. Horton, J. M. (1980). Use of anaesthesia. Care of the unconscious.. BMJ. https://doi.org/10.1136/bmj.281.6232.38
322. Howland, R. H. (2014). Psychotropic Medication Use:What Will It Do To My Liver?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20140722-01
323. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
324. Hughes, J. R., Higgins, S. T., & Bickel, W. K. (1994). Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03744.x
325. Huss, A., & Vermeulen, R. (2014). Neurodegenerative Diseases and ELF-EMF. CRC Press eBooks. https://doi.org/10.1201/b16968-15
326. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
327. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
328. Ilyas, A., Szapiel, M., & Foreman, P. M. (2022). Kernohan’s notch phenomenon: A paradoxical neurological finding. Journal of Clinical Images and Medical Case Reports. https://doi.org/10.52768/2766-7820/1939
329. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
330. Iqbal, M. (2015). Identification and Prevention of Serotonin Syndrome. International Journal of Emergency Mental Health and Human Resilience. https://doi.org/10.4172/1522-4821.1000217
331. Irakkam, M. P. B. D., Joseph, J. H. M., & Kandasamy, M. (2024). Aberrant Hippocampal Neuroregenerative Plasticity in Schizophrenia: Reactive Neuroblastosis as a Possible Pathocellular Mechanism of Hallucination. Neurosignals. https://doi.org/10.33594/000000712
332. Ishizuka, K., Shikino, K., Li, Y., Yokokawa, D., Tsukamoto, T., Yanagita, Y., Kojima, J., Yamashita, S., Noda, K., Uehara, T., & Ikusaka, M. (2023). The differential diagnosis of medical and psychogenic disease in primary care. Journal of General and Family Medicine. https://doi.org/10.1002/jgf2.661
333. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
334. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
335. Jaffee, M. S., Broshek, D. K., & Svingos, A. M. (2023). What Is a Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190630119.003.0001
336. Jalal, B. (2018). The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology. https://doi.org/10.1007/s00213-018-5042-1
337. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
338. Japardi, I. (2002). ASPEK NEUROLOGIK GANGGUAN BERJALAN.
339. Johansson, B., Andréll, P., Mannheimer, C., & Rönnbäck, L. (2022). [Mental fatigue - possible explanations, diagnostic methods and possible treatments].. PubMed.
340. Jukić, M. K., Mimica, N., & Lucijanić, D. (2024). DEPRESSION IN ELDERLY PERSONS. Proceedings. https://doi.org/10.62598/9thicva.019
341. Kahler, S. G., & Fahey, M. (2003). Metabolic disorders and mental retardation. American Journal of Medical Genetics Part C Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.10018
342. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
343. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
344. Kane, J. M. (1997). The New Antipsychotics. Journal of Psychiatric Practice. https://doi.org/10.1097/00131746-199711000-00003
345. Kanellopoulos, D., & Vallejo, P. S.-B. (2019). Substance Related Cognitive Dysfunction in Aging. Clinical handbooks in neuropsychology. https://doi.org/10.1007/978-3-319-93497-6_19
346. Kantharia, S. J., Sn, G., & Patel, K. B. (2022). Age Related Neurodegenerative Disorders w.s.r to Dementia. International Journal of Ayurveda and Pharma Research. https://doi.org/10.47070/ijapr.v10i6.2367
347. Kapała, W., Kapała, A., & Wojtyła-Buciora, P. (2023). Psychoactive Substances and Selected Health Problems Related to Their Use. https://doi.org/10.2478/bgbl-2023-0036
348. Kaplan, H., Sadock, B. J., & Grebb, J. A. (1994). Kaplan and Sadock's synopsis of psychiatry : behavorial sciences, clinical psychiatry. Williams & Wilkins eBooks.
349. Kapoor, K. (2003). Novel Potential Antimigraine Compounds: Carotid and Systemic Haemodynamic Effects in a Porcine Model of Migraine.
350. Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021). Clinical characteristics and treatment of treatment-resistant bipolar depression. Psychiatriki. https://doi.org/10.22365/jpsych.2021.048
351. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
352. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
353. Kasatkin, D. S. (2006). [Possible mechanisms of chronic fatigue syndrome in multiple sclerosis].. PubMed.
354. Kaur, G., Invally, M., Mistry, H., Dicholkar, P., & Bhullar, S. K. (2019). Role of Herbs and Their Delivery Through Nanofibers in Pharmacotherapy of Depression. Apple Academic Press eBooks. https://doi.org/10.1201/9780429487804-13
355. Kaur, K., Panda, N., Mahajan, S., & Ram, T. (2024). Irresistible Laughter—A Rare Presentation of Intracranial Tumor: Irony of Neurocircuitry. Asian Journal of Neurosurgery. https://doi.org/10.1055/s-0043-1772767
356. Kaware, M. A. S., Dudhe, M. P. V., Chavhan, M. N. R., Naveria, M. A., & Rajeshwari, K. R. (2024). An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it’s Interaction with Other Drugs which are Already in use Respect to Other Disease. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-18578
357. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
358. Kašpárek, T., Dreisig, M., & Barteček, R. (2014). Alkoholový odvykací stav a delirium - od patofyziologie k léčbě. Česká a slovenská neurologie a neurochirurgie.
359. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
360. Kenneth, M. H. (2004). Intentional neglect. Frontiers in bioscience. https://doi.org/10.2741/1261
361. Khaikin, Y., & Mercimek‐Andrews, S. (2016). STXBP1 Encephalopathy with Epilepsy.
362. Khune, A. A., Rathod, H., Deshmukh, S. P., & Chede, S. B. (2023). Mental health, depressive disorder and its management: A review. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2023.25.2.0464
363. Kidd, C. J., Kathari, Y. K., Dalton, K.-N., & Hack, N. (2023). Drug and Toxin-Induced Cerebellar Ataxias. Anesthesia & Clinical care. https://doi.org/10.24966/acc-8879/100084
364. Kim, J.-B., & Sung-Won, J. (2013). 공존하는 불안장애와 물질사용장애가 주요우울증에 미치는 영향.
365. King, A., Rawitt, R. R., Barboza, K. C., & Hollander, E. (2003). Cognitive and Neuropsychological Assessment of Children with Autism Spectrum Disorders. CRC Press eBooks. https://doi.org/10.3109/9780203911723-9
366. Kinsey, S. G., Vanegas, O., Trexler, K. R., Steele, F., & Eckard, M. L. (2021). Neuroendocrinology of Stress and Addiction. Oxford Research Encyclopedia of Neuroscience. https://doi.org/10.1093/acrefore/9780190264086.013.252
367. Kirakosyan, G. (2022). Understanding psychosis: diagnosis and clinical presentation (updates for clinicians). World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2022.13.1.0759
368. Kirakosyan, G. (2022). Understanding psychosis: treatment and rehabilitation (updates for clinicians). World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2022.13.1.0006
369. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
370. Knardahl, S. (2005). Psychological and social factors at work: contribution to musculoskeletal disorders and disabilities.. Giornale italiano di medicina del lavoro ed ergonomia.
371. Knupp, K. G., & Wirrell, E. (2014). Progressive myoclonic epilepsies. Neurology. https://doi.org/10.1212/wnl.0000000000000091
372. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
373. Kocabaşoğlu, N., Karaçetin, G., Bayar, R., & Demir, T. (2012). A Review of the Etiology Delirium. InTech eBooks. https://doi.org/10.5772/32411
374. Kokurcan, A., & Atbaşoğlu, C. (2015). [Differential Diagnosis of Schizophrenia: Psychotic Symptoms in Neurodevelopmental Disorders and Psychotic Disorders due to other Medical Conditions].. PubMed.
375. Koltsov, I., Yasamanova, A. N., Aryasova, I. K., & Boiko, A. N. (2024). Posterior reversible encephalopathy syndrome in autoimmune disorders. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro202412407250
376. Kondo, T., & Ishiguchi, H. (2007). 3. Drug Induced Dyskinesia. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.96.1621
377. Konez, O., Pascual-Castroviejo, I., Rocco, C. D., & Ruggieri, M. (2008). Sturge-Weber Syndrome. https://doi.org/10.1007/978-3-211-69500-5_10
378. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
379. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
380. Koob, G. F., Kandel, D. B., Baler, R., & Volkow, N. D. (2015). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9781118753378.ch22
381. Koshy, R., & Sudha, P. (2011). Nonconvulsive status epilepticus: An unusual cause of postoperative unresponsiveness following general anaesthesia. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.79901
382. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
383. Krishnan, J. (2024). MDMA (3,4-methylenedioxy-methamphetamine). BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010004
384. Krishnan, J. (2024). Methamphetamine. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010006
385. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
386. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
387. Kukla, U., Łabuzek, K., Chronowska, J., Krzystanek, M., & Okopień, B. (2015). [Mental disorders in digestive system diseases - internist's and psychiatrist's insight].. PubMed.
388. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
389. Kuriakose, T. (2013). Effectiveness of Speech Therapy in Neurogenic Stuttering: A Case Study.
390. Lai, J., Shi, Y., Lin, S., & Chen, X. (2022). Metabolic disorders on cognitive dysfunction after traumatic brain injury. Trends in Endocrinology and Metabolism. https://doi.org/10.1016/j.tem.2022.04.003
391. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
392. Lam, R. W. (2018). Clinical features and diagnosis. Depression. https://doi.org/10.1093/med/9780198804147.003.0004
393. Lambert, M., Schimmelmann, B. G., Karow, A., & Naber, D. (2003). Subjective Well-being and Initial Dysphoric Reaction under Antipsychotic Drugs - Concepts, Measurement and Clinical Relevance. Pharmacopsychiatry. https://doi.org/10.1055/s-2003-45128
394. Lambert, T. (2007). Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes.. PubMed.
395. Lane, R., & Baldwin, D. S. (1997). Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199706000-00012
396. Lara-Plaza, O., Solís‐Navarro, L., Rivera‐Lillo, G., & Torres‐Castro, R. (2022). Cognitive and motor performance effects of non-invasive brain stimulation in patients with traumatic brain injury: A meta-analysis of randomised controlled trials. https://doi.org/10.37766/inplasy2022.4.0067
397. Larrea, S. T., Fernández‐Aranda, F., Jiménez‐Múrcia, S., & Granero, R. (2016). Nuevos retos en el tratamiento de los trastornos relacionados con la impulsividad.
398. Lassal, R., Laurent, M., & Purper‐Ouakil, D. (2011). [Early signs of mental disorders in children aged 3-12 years].. PubMed.
399. Lathers, C. M., Schraeder, P., & Bungo, M. W. (2010). Syncope, Seizures, and SUD EP. CRC Press eBooks. https://doi.org/10.1201/b10317-23
400. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
401. Laviano, A., Inui, A., Marks, D. L., Meguid, M. M., Pichard, C., Fanelli, F. R., & Seelaender, M. (2008). Neural control of the anorexia-cachexia syndrome. AJP Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.90252.2008
402. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
403. Lawson, J. (2002). Drug-Induced Metabolic Bone Disorders. Seminars in Musculoskeletal Radiology. https://doi.org/10.1055/s-2002-36727
404. Lee, X.-C., Lu, T., Zheng, W., & Xue, Y. (2025). STRESS COMBINED WITH EXTINCTION PREVENTS COCAINE RELAPSE BY DISRUPTING MEMORY. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.175
405. Lee, Y. L., Wong, J., & Ng, S. Y. (2022). Delirium in patients following general anaesthesia. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.202228
406. Lee‐Chiong, T. (2008). Medications and Their Effects on Sleep. https://doi.org/10.1093/oso/9780195306590.003.0016
407. Lee‐Chiong, T. (2008). Parasomnias and Abnormal Sleep-Related Movements. https://doi.org/10.1093/oso/9780195306590.003.0007
408. Lee‐Chiong, T. (2008). Psychiatric and Behavioral Disorders. https://doi.org/10.1093/oso/9780195306590.003.0011
409. Lehotský, J., Bürda, J., Danielisová, V., Gottlieb, M., Kaplán, P., & Sániová, B. (2009). Ischemic Tolerance: The Mechanisms of Neuroprotective Strategy. The Anatomical Record. https://doi.org/10.1002/ar.20970
410. Leiguarda, R. (2003). Distinctive Features of Apraxia in Corticobasal Degeneration and Other Neurological Illnesses. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-326-2_10
411. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
412. Lemogne, C., Pitron, Jy, R., Limosin, F., & Cathébras, P. (2019). What attitude towards a patient with somatoform disorder?. PubMed.
413. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
414. Lewis, S., Tarrier, N., & Drake, R. (2005). Integrating non-drug treatments in early schizophrenia. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.187.48.s65
415. Leyton, M. (2022). Does stimulant drug–induced sensitization occur in primates?. Journal of Psychiatry and Neuroscience. https://doi.org/10.1503/jpn.220055
416. Li, H., Xu, G., Zhu, W., & Yuan, G. (2022). Editorial: Application of natural medicinal products in preventing and ameliorating aging-caused cognitive impairment. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1059398
417. Lichtenstein, S. V. (2015). Multiple Sklerose – welche Optionen bietet die Ernährungstherapie?. Aktuelle Ernährungsmedizin. https://doi.org/10.1055/s-0035-1552701
418. Lindesay, J., & Macdonald, A. (1997). Delirium. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511570070.011
419. Lipowski, Z. J. (1987). Delirium (Acute Confusional States). JAMA. https://doi.org/10.1001/jama.1987.03400130103041
420. Lipowski, Z. J. (1987). Delirium (acute confusional states). JAMA. https://doi.org/10.1001/jama.258.13.1789
421. Liu, M. (2009). 47名地震灾区异地诊治患者应激评价水平分析. Zhonghua xingwei yixue yu naokexue zazhi. https://doi.org/10.3760/cma.j.issn.1674-6554.2009.09.022
422. Liu, Y., Zhao, J., Fan, X., & Guo, W. (2019). Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2019.00286
423. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
424. Lockhart, P. J. (2001). Fetal alcohol spectrum disorders for mental health professionals - a brief review. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200109000-00007
425. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
426. Luccarelli, J., McCoy, T. H., Yip, A. G., Seiner, S. J., & Henry, M. (2022). Borderline personality disorder traits are not associated with a differential change in global cognitive function during acute course ECT. Brain stimulation. https://doi.org/10.1016/j.brs.2022.04.006
427. Lyketsos, C. G. (2012). F1‐01‐02: Tackling overlap of neuropsychiatric symptoms in Alzheimer's and other dementias: Toward a unified approach to evaluation and treatment. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.191
428. López-Ibor, J. J., & López‐Ibor, M. (2003). Research on obsessive-compulsive disorder. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200304002-00013
429. López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022). 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.990405
430. MacCulloch, T., & Lowenstein, L. F. (2009). Do the Causes of Psychotic Symptoms Matter?. Issues in Mental Health Nursing. https://doi.org/10.1080/01612840903177464
431. MacCulloch, T., & Lowenstein, L. F. (2009). Do the Causes of Psychotic Symptoms Matter?. Issues in Mental Health Nursing. https://doi.org/10.3109/01612840903177464
432. Machado, C. F. A., & Siqueira, E. C. D. (2022). Uma abordagem geral do Transtorno de Estresse Pós-Traumático: revisão de literatura. Revista Eletrônica Acervo Médico. https://doi.org/10.25248/reamed.e10939.2022
433. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Cognitive, behavioural and psychological symptoms. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.015
434. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Problems with muscles and movement. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.009
435. Mahadevan, J., D’cruz, M., Chand, P., & Murthy, P. (2019). An interesting presentation of psychotic catatonia in an elderly patient with alcohol dependence. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_33_19
436. Mailman, R. B., & Murthy, V. (2010). Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?. Current Pharmaceutical Design. https://doi.org/10.2174/138161210790361461
437. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
438. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
439. Malik, A. K., Melookaran, A. M., Simon, G. S., & Zhu, Q. (2014). Effects of Substance Abuse on the Cardiovascular System and Its Management. Substance Abuse. https://doi.org/10.1007/978-1-4939-1951-2_43
440. Malin, H., & Saleh, F. M. (2007). Paraphilias: Clinical and Forensic Considerations.
441. Mallick, K., & Banerjee, S. (2023). Plants Affecting Serotonergic Neurotransmission. https://doi.org/10.1007/978-981-99-7703-1_11
442. Mallik, D., Dingle, T., & Bowen, S. (2022). Meditation and Yoga in the Treatment of Addictive Disorders. https://doi.org/10.1007/978-981-16-6913-2_21
443. Maneeton, N., & Maneeto, B. (2013). Management of Delirium. InTech eBooks. https://doi.org/10.5772/52756
444. Mangastuti, R. S., Rahardjo, S., & Wargahadibrata, A. H. (2016). Penatalaksanaan Anestesi pada Operasi Epilepsi. Jurnal Neuroanestesi Indonesia. https://doi.org/10.24244/jni.vol5i2.64
445. Manso-Calderón, R., & Sevillano-García, M. D. (2010). [Nonmotor symptoms in Parkinson's disease and deep brain stimulation].. Revista de Neurología.
446. Maramis, M. M. (2009). Mengenal Gangguan Mood pada Perempuan.
447. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
448. Marchand, D. K., & McCormack, S. (2019). Codeine for Acute Pain in Patients Undergoing Orthopedic Surgery: A Review of Clinical Effectiveness [Internet].
449. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
450. Martínez‐Castrillo, J. C., Vela, L., Val, J. D., & Alonso‐Cánovas, A. (2011). Nonmotor Disorders and Their Correlation With Dopamine. The Neurologist. https://doi.org/10.1097/nrl.0b013e318239669f
451. María, A., Sancho, R., & Pita, B. L. (2005). Trastornos de ansiedad en la infancia y en la adolescencia.
452. Masgutova, S., Wenberg, S., & Retschler, M. (2008). MASGUTOVA METHOD OF REFLEX INTEGRATION FOR CHILDREN WITH CEREBRAL PALSY.
453. Mattoo, S. K., Grover, S., & Gupta, N. (2010). Delirium in general practice.. PubMed.
454. Mattson, R. H. (2004). Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.. PubMed.
455. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
456. Mc, M.-S. (1993). [Post-traumatic stress syndrome in children].. PubMed.
457. McArdle, P., & Angom, B. (2012). Adolescent substance misuse: an update on behaviours and treatments. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.106.003327
458. McCullough, P. K. (1991). Geriatric depression: atypical presentations, hidden meanings.. PubMed.
459. McEwen, B. S. (2003). Early life influences on life‐long patterns of behavior and health. Mental Retardation and Developmental Disabilities Research Reviews. https://doi.org/10.1002/mrdd.10074
460. McKnight, R., Price, J., & Geddes, J. (2019). Introduction to psychiatry. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198754008.003.0005
461. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
462. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
463. Medjkane, F., Bohet, M., Ister, M., Cohen, D., Parenti, A., Janati, M., Mention, K., Dobbelaere, D., & Jardri, R. (2021). Onset of psychiatric signs and impaired neurocognitive domains in inherited metabolic disorders: A case series. JIMD Reports. https://doi.org/10.1002/jmd2.12133
464. Meeusen, R., Cutsem, J. V., & Roelands, B. (2020). Endurance exercise‐induced and mental fatigue and the brain. Experimental Physiology. https://doi.org/10.1113/ep088186
465. Meléndez, R. I., & Kalivas, P. W. (2008). The Basic Science of Addiction. https://doi.org/10.1093/oso/9780195300550.003.0006
466. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
467. Meyer, J. S., Obara, K., & Muramatsu, K. (1993). Diaschisis. Neurological Research. https://doi.org/10.1080/01616412.1993.11740164
468. Meza-Ruiz, W., & Zúñiga-Escobar, G. (2023). Hematoma cerebral intraparenquimatoso e intraventricular por cocaína: reporte de un caso. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272023000100064
469. Michel, J., Gisselbaek, A., Gauthey, L., & Zelger, G. L. (1993). [Non-compliant drug taking in elderly subjects].. PubMed.
470. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
471. Miettinen, O. S., & Flegel, K. M. (2003). Elementary concepts of medicine: VII. Course of illness: manifestations, complications, outcome. Journal of Evaluation in Clinical Practice. https://doi.org/10.1046/j.1365-2753.2003.00420.x
472. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
473. Mihanović, M., Restek-Petrović, B., Bodor, D., Molnar, S., Orešković, A., & Presečki, P. (2010). Suicidality and side effects of antidepressants and antipsychotics.. PubMed.
474. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
475. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
476. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
477. Miller, S. P., & Latal, B. (2009). Neurocognitive outcomes of term infants with perinatal asphyxia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511581281.050
478. Miller, S., Schwemmle, C., Jungheim, M., Kühn, D., & Ptok, M. (2015). [Medication-induced dysphagia : A review]..
479. Milovac, Ž., Pisk, S. V., Silić, A., & Mihanović, M. (2010). Diagnostic dilemma – serotonin syndrome or medication induced delirium:. Socijalna psihijatrija.
480. Miranda, C. A. C., & Varona, M. T. B. (2013). Isquemia cerebral experimental y sus aplicaciones en la investigación en neurociencias. DOAJ (DOAJ: Directory of Open Access Journals).
481. Miyata, H., & Yanagita, T. (1998). [Mechanism of nicotine dependence].. PubMed.
482. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
483. Moal, M. L. (2008). Negative affects are parts of the addiction syndrome. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x08004871
484. Moch, S. (2011). Dysthymia: more than "minor".
485. Moch, S. (2011). Dysthymia: more than “minor” depression. South African Pharmaceutical Journal.
486. Moh, D., & Sansone, R. A. (2015). Factitious Disorder Manifesting as Hematemesis and Hematochezia. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.14l01693
487. Mohr, P. (2022). Treating Catatonia: a Blind Spot of Psychiatry?. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.143
488. Moncrieff, J. (2008). An Alternative Drug-Centred Model of Drug Action. https://doi.org/10.1007/978-0-230-58944-5_2
489. Monotti, R. (1993). [Drug emergencies].. PubMed.
490. Morse, S. J. (1995). The “new syndrome excuse syndrome”. Criminal Justice Ethics. https://doi.org/10.1080/0731129x.1995.9991984
491. Mortier, P., Vandenbulcke, M., & Gabriëls, L. (2014). [Confusional arousal: a rare cause of self-injurious behaviour].. PubMed.
492. Morylowska-Topolska, J., Ziemiński, R., Molas, A., Gajewski, J., Flis, M., Stelmach, E., & Karakuła‐Juchnowicz, H. (2016). Schizophrenia and anorexia nervosa – reciprocal relationships. A literature review. Psychiatria Polska. https://doi.org/10.12740/pp/onlinefirst/63514
493. Moryś, J. M., Jeżewska, M., & Korzeniewski, K. (2015). Neuropsychiatric manifestations of some tropical diseases. International Maritime Health. https://doi.org/10.5603/imh.2015.0009
494. Moshki, M., & Kharazmi, A. (2015). Application of the PRECEDE Model to Understanding Postnatal Depression.. PubMed.
495. Mossaheb, N., Schloegelhofer, M., Schaefer, M., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G., & Amminger, G. P. (2012). Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-215-5_9
496. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
497. Moyo⃰, G. P. K. (2020). Perinatality and Childbirth as a Factor of Decompensation of Mental Illness: The Case of Depressive States in Newly Delivered Cameroonian Women. Archives in Biomedical Engineering & Biotechnology. https://doi.org/10.33552/abeb.2020.04.000592
498. Mueller‐Pfeiffer, C., & Wittmann, L. (2013). Preliminary Investigation of the Reliability and Validity of the German Version of the State Scale of Dissociation (SSD). Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000106
499. Mulak, A. (2003). Testing of visceral sensitivity.. Journal of Physiology and Pharmacology.
500. Mumdzhiev, H., & Slancheva, B. (2013). [Intrauterine hypotrophy and programming the health status. Late problems in newborns with intrauterine hypotrophy].. PubMed.
501. Munster, B. C. V., Rooij, S. E. D., & Inouye, S. K. (2016). Delirium, drugs, toxins. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0022
502. Munteanu, D., Vlase, A., Perţea, L., Felea, M. G., Rusu, A., Ciorap, R., & Anton-Prisacariu, B. (2022). Neuropsychic pathology in the context of anterior chest pain. Bulletin of Integrative Psychiatry. https://doi.org/10.36219/bpi.2022.3.06
503. Murcia, S. V. N. (2016). La bebida compulsiva en polidipsia inducida por programa como rasgo de vulnerabilidad psicopatológica en ratas: implicaciones de la serotonina en su desarrollo y mantenimiento.
504. Murphy, D. L., Timpano, K. R., Wheaton, M. G., Greenberg, B. D., & Miguel, E. C. (2010). Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2010.12.2/dmurphy
505. Muskin, P. R. (2014). DSM-5 Self-Exam Questions: Test Questions for the Diagnostic Criteria.
506. Mw, H., Eg, G., Hj, B., & Weel, C. V. (1997). [Chronic fatigue syndrome].. PubMed.
507. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
508. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
509. N.G., E., & Zashchirinskaia, O. V. (2024). ATTITUDE TO THE DISEASE AND ADHERENCE TO TREATMENT OF PATIENTS WITH CONSEQUENCES OF STROKE. “Educational bulletin “Consciousness”. https://doi.org/10.26787/nydha-2686-6846-2024-26-2-31-39
510. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
511. Nadha, T. F. (2017). Factitious Disorder (Munchausen Syndrome). International Journal of Neurological Nursing. https://doi.org/10.37628/ijnn.v3i2.413
512. Naeije, G. (2022). None. International Journal of Clinical Studies and Medical Case Reports. https://doi.org/10.46998/ijcmcr.17.4
513. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
514. Nakajima, T., & Kanno, O. (1998). [Drug-induced sleep disorders].. PubMed.
515. Nakamura, A., & Tanaka, K. (2023). A boy with dissociative symptoms who benefited from biopsychosocial assessment. Pediatrics International. https://doi.org/10.1111/ped.15502
516. Narayan, J. P., Verma, D., & Islam, R. (2022). Chronic Mania-A Case Report. International Journal of Psychiatric Nursing. https://doi.org/10.37506/ijpn.v9i1.18831
517. Newman, L. C. (2008). Classification and Diagnosis of Secondary Headaches: Substances, Metabolic Disorders, EENT Causes, and Neuralgias. https://doi.org/10.1093/oso/9780195366730.003.0009
518. Nigg, J. T. (2003). Response Inhibition and Disruptive Behaviors. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1301.018
519. Nijenhuis, E. R. S. (2022). Somatoform Dissociation, Agency, and Consciousness. Routledge eBooks. https://doi.org/10.4324/9781003057314-40
520. Nikogosyan, G., Torncello, E. R., & Macdonald, S. (2024). Secondary Mania of Medical and Neurological Disorders. IntechOpen eBooks. https://doi.org/10.5772/intechopen.1007693
521. Norman, E. M., Ferner, R. E., & Rawlins, M. D. (1995). Effects of drugs on behaviour. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198548263.003.0005
522. Noël, X., Bechara, A., Brevers, D., Verbanck, P., & Campanella, S. (2010). Alcoholism and the Loss of Willpower. Journal of Psychophysiology. https://doi.org/10.1027/0269-8803/a000037
523. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
524. Ojeda, A. A. A., Li, B., & Patel, R. (2023). Substance-Induced Psychotic Disorder. Psychiatric Annals. https://doi.org/10.3928/00485713-20230314-01
525. Ojeda, B. S., Salazar, A., Dueñas, W. A. M., & Failde, I. (2011). El deterioro cognitivo: un factor a tener en cuenta en la evaluación e intervención de pacientes con dolor crónico. Revista de la Sociedad Española del Dolor.
526. Oliveira, S., Kallaur, A., & Reiche, E. M. V. (2014). Oxidative Stress in Stroke. CRC Press eBooks. https://doi.org/10.1201/b16653-28
527. Olmedo, A., & Rolando, M. (2015). Informe psicológico pericial: situación de violencia intrafamiliar, “maltrato física, psicológica y sexual”, grado de afectación psicológico..
528. Olson, D. M., Westermarck, T., & Ekvall, S. W. (2005). Seizures And Epilepsy. https://doi.org/10.1093/oso/9780195165647.003.0010
529. Os, J. V., Praag, H. M. V., & Kloet, E. R. D. (2004). Stress, the brain and depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544422.010
530. Oscar‐Berman, M., & Mosher, S. M. (2010). Brain Injuries. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0143
531. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
532. Ownby, R. L. (2006). Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults.. PubMed.
533. Ozdemir, D., & Sahni, S. (2019). Conversion Disorder (Functional Neurological Symptom Disorder) Masquerading as Multiple Sclerosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.4893
534. Page, R. D. (1983). Cerebral dysfunction associated with alcohol consumption.. PubMed.
535. Paillé, F., Pissochet, P., & Pirollet, P. (1993). [Acute alcoholic intoxication and drugs].. PubMed.
536. Pairas, G., Perperopoulou, F., Tsoungas, P. G., & Varvounis, G. (2017). The Isoxazole Ring and Its <i>N</i>‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics. ChemMedChem. https://doi.org/10.1002/cmdc.201700023
537. Palmer, B. A. (2016). Substance Use Disorders, Personality Disorders, and Eating Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190464868.003.0069
538. Palmer, B. W., McClure, F. S., & Jeste, D. V. (2001). Schizophrenia in Late Life: Findings Challenge Traditional Concepts. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220127883
539. Palmieri, D. T. (1991). Clearing Up the Confusion: ADVERSE EFFECTS OF MEDICATIONS in the Elderly. Journal of Gerontological Nursing. https://doi.org/10.3928/0098-9134-19911001-09
540. Parada, S. M. (2018). Mecanismos neurobiológicos e inmunes que subyacen al déficit en control inhibitorio: estudios preclínicos.
541. Parker, R. S. (2012). Chronic Posttraumatic Disorders of Consciousness. CRC Press eBooks. https://doi.org/10.1201/b10562-14
542. Parker, R. S. (2012). Introduction to the Postconcussion Syndrome. CRC Press eBooks. https://doi.org/10.1201/b10562-2
543. Parolaro, D., Viganò, D., & Rubino, T. (2005). Endocannabinoids and Drug Dependence. Current Drug Targets - CNS & Neurological Disorders. https://doi.org/10.2174/156800705774933014
544. Parrott, A. (2015). The Adverse Psychiatric Consequences of Recreational Stimulant Drugs Such as Methamphetamine, Cocaine, Ecstasy/mdma, and Mephedrone: a Unified Psychobiological Explanation.. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30842-7
545. Pascual‐Leone, Á., Ramachandran, V. S., Cole, J., Sala, S. D., Manly, T., Mayes, A. R., & Sacks, O. (2011). The Paradoxical Brain. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511978098
546. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
547. Pathak, M., & Brashear, A. (2009). Spasticity. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575761.015
548. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
549. Pattanashetti, L., & Doddanavar, A. (2022). Alcohol Induced Cerebellar Ataxia: A Case Report. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2022.14.25
550. Patti, L., & Gupta, M. (2019). Change In Mental Status. StatPearls.
551. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
552. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
553. Payne‐James, J., Perera, C., & Aggrawal, A. (2023). Neglect. CRC Press eBooks. https://doi.org/10.1201/9781003138754-54
554. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
555. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
556. Pereira, S. M. P., Guimarães, S. K. G., Marques, A., & Borges, S. (2008). Electroconvulsivotherapy in the elderly, indications, risks and side-effects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.01.611
557. Peretti, C.-S., Ferreri, F., & Crucis, B. (2009). Troubles cognitifs dans la dépression. La Lettre du psychiatre.
558. Perkinson, R. R., & Jongsma, A. E. (1997). The Chemical Dependence Treatment Planner.
559. Petruševičienė, D., & Kriščiūnas, A. (2003). [Occupational therapy for patients after stroke].. PubMed.
560. Phan, S. V. (2016). Medication adherence in patients with schizophrenia. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217416636601
561. Pich, E. M., Heidbreder, C., Mugnaini, M., & Teneggi, V. (2003). Molecular and Behavioral Aspects of Nicotine Dependence and Reward. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_16
562. Pitkanen, M. L., Stevens, T. H., & Kopelman, M. D. (2010). Neuropsychiatric disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.2604
563. Pivac, N., Perković, M. N., Erjavec, G. N., Dodig‐Ćurković, K., Ćurković, M., Škledar, M., & Mück‐Šeler, D. (2010). Molecular markers of behavioral and emotional disorders.
564. Poian, L. R., & Chiavegatto, S. (2023). Serotonin Syndrome: The Role of Pharmacology in Understanding Its Occurrence. Cureus. https://doi.org/10.7759/cureus.38897
565. Polinsky, R. J. (2019). Shy-Drager Syndrome and Multiple System Atrophy. CRC Press eBooks. https://doi.org/10.1201/9781315141367-6
566. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
567. Portes, V. D., & Héron, D. (2020). Trastornos del desarrollo intelectual. Contraste.
568. Potocnik, F. (2013). Dementia : The South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders. South African Medical Journal.
569. Prajapati, B., Agarwal, A., Garg, D., Garg, A., Pandit, A., Radhakrishnan, D. M., & Srivastava, A. (2024). Delayed post-hypoxic parkinsonism with leukoencephalopathy associated with carbon monoxide poisoning. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_37_24
570. Praško, J., Raszka, M., & Pastucha, P. (2009). Dissociative Disorders - Clinical Manifestation and Management. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)70376-1
571. Prelipceanu, D., & Barbu, R. E. (2017). Burnout syndrome. Romanian Journal of Psychiatry & Psychotherapy. https://doi.org/10.37897/rjpp.2017.2.1
572. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
573. Pressman, M. R. (2008). Diagnostic Tools for Parasomnias. CRC Press eBooks. https://doi.org/10.3109/9781420019926-40
574. Price, C. C., McCraney, S. E., Wiggins, M. E., Alonso, C. H., Dion, C., Arias, F., Hamlet, K., & Tighe, P. (2023). Perioperative Cognitive Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108936941.034
575. Prudenzano, M. P., Puca, F. M., Savarese, M., Genco, S., & Specchio, L. M. (1997). Stress, mood disorders and memory in headache.. PubMed.
576. Pujol, R., & Puel, J. (1999). Excitotoxicity, Synaptic Repair, and Functional Recovery in the Mammalian Cochlea: A Review of Recent Findings. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1999.tb08646.x
577. Pérez, Y. M. M., Ortega, D. L. G., & Torres, S. V. L. (2022). AGITACIÓN PSICOMOTRIZ. PUERTO MADERO EDITORIAL eBooks. https://doi.org/10.55204/pmea.3.c10
578. Płytycz, B., & Seljelid, R. (2002). Stress and immunity: minireview.. PubMed.
579. Quartini, A., Pacitti, F., Bersani, G., & Iannitelli, A. (2018). From Adolescent Neurogenesis to Schizophrenia: Opportunities, Challenges and Promising Interventions. Biomedical Reviews. https://doi.org/10.14748/bmr.v28.4452
580. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
581. Qureshi, M. A., & Wasti, S. A. (2014). Lay-off Survivor Sickness Syndrome (Investigating the Lasting Impact on Performance of Survivors in the Context of Age and Gender in Private Sector Organizations of Pakistan). International Journal of Human Resource Studies. https://doi.org/10.5296/ijhrs.v4i3.6078
582. Radulović, N., Mišković, M., Zoric, D., Maglov, T., & Ilić, D. (2008). Crisis intervention. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.01.569
583. Rahmani, M., Ahmadi, S., & Moghaddam, H. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose.
584. Rahmani, S. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose Methamphetamine. Journal of Clinical Toxicology. https://doi.org/10.4172/2161-0495.1000111
585. Raičević, B., Janković, S. V., Gojak, R., Dabanović, V., & Јаnkovic, S. (2023). Long-term outcomes in refractory status epilepticus. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2023.2292143
586. Ramachandran, V., Ding, B., George, R., & Novakovic, M. (2018). Conservative management of severe serotonin syndrome with coma, myoclonus, and crossed-extensor reflex complicated by hepatic encephalopathy. Baylor University Medical Center Proceedings. https://doi.org/10.1080/08998280.2017.1400874
587. Ramsay, D. A. (2014). Ethanol, Trauma, and the Brain. Academic Forensic Pathology. https://doi.org/10.23907/2014.030
588. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
589. Rani, M. K. S., Fathima, S. T., Gayathri, S. L., Pavani, M., & Swathi, Y. (2022). Detection of Autism Spectrum Disorder using Machine Learning. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-7600
590. Ransom, S. B., & Moldenhauer, J. S. (1998). Premenstrual Syndrome. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.1998.04.872
591. Rao, S. (2016). Prolonged coma after anesthesia. Journal of Anaesthesiology Clinical Pharmacology. https://doi.org/10.4103/0970-9185.173339
592. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
593. Realpe, B. L. C. (2013). Estudio comparativo de la acción psicofarmacológica y analgésica de extractos de plantas de uso terapéutico tradicional con antidepresivos inhibidores selectivos de la recaptación de monoaminas.
594. Ree, J. M. V., Koob, G. F., Higgins, G. A., Naranjo, C. A., & Zvartau, E. (1995). Neurohormonal Systems Underlying Drug Addiction: Relevance for Treatment Strategies. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7218-8_27
595. Renzullo, A. M., Benvenuto, S., Nait, G., & Pennesi, M. (2024). L'enuresi notturna: in quadramento e gestione. Medico e Bambino. https://doi.org/10.53126/meb43499
596. Resch, M. (2010). The psychological factors affecting athletic performance. Orvosi Hetilap. https://doi.org/10.1556/oh.2010.28890
597. Richardson, S. A., & Koller, H. (1994). Mental And Mental Retardation. https://doi.org/10.1093/oso/9780195075168.003.0010
598. Richter, W., & Otto, C. (1997). [Hypoglycemia. Symptoms, differential diagnosis, therapy].. PubMed.
599. Ridzoň, P. (2022). Benign fasciculation syndrome. Neurologie pro praxi. https://doi.org/10.36290/neu.2021.075
600. Riederer, P., & Gerlach, M. (1993). The Pathophysiological Basis of Parkinson’s Disease. Milestones in drug therapy. https://doi.org/10.1007/978-3-0348-6348-3_2
601. Rigaud, J., Lheureux, P., & Sauder, P. (2006). Prise en charge symptomatique : neurologique, respiratoire, hémodynamique et hépatique des intoxications graves par médicaments et substances illicites. Réanimation. https://doi.org/10.1016/j.reaurg.2006.08.002
602. Riofrío, I. P. B., Jefe, M., De, D., Mental, S., Miller, H., Mt, S., Psiquiatría, D., Dra, H., Velastegui, G. N. J., medico, Psc, R., Alexandra, C., & Torres, L. (2019). Síndrome Neuroléptico Maligno: A propósito de un caso clínico. https://doi.org/10.36015/cambios.v16.n1.2017.279
603. Rizal, R. R., & Fiana, D. N. (2019). Sindrom Serotonin. Medical Profession Journal of Lampung. https://doi.org/10.53089/medula.v11i2.186
604. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
605. Robinson, M. J., Robinson, T. E., & Berridge, K. (2018). The Current Status of the Incentive Sensitization Theory of Addiction. Routledge eBooks. https://doi.org/10.4324/9781315689197-29
606. Robinson, T. E. (2014). Sensitization to Drugs.
607. Robison, D., & Hunt, S. D. (2005). Sudden In-Custody Death Syndrome.
608. Robles, L. A. (2015). Serotonin Syndrome Induced by Fentanyl in a Child. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000100
609. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
610. Rodríguez, E. O., Martı́nez-Raga, J., Gómez, M. C., Gálvez, B. P., Ferragut, A. S., & Martínez, G. C. (2003). Complicaciones físicas del consumo de drogas recreativas. Adicciones. https://doi.org/10.20882/adicciones.462
611. Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults.. Journal of Abnormal Psychology. https://doi.org/10.1037/0021-843x.100.2.214
612. Roland, P. S., & Blau, P. (2016). Diagnosis and Management of Balance Disturbances Following Traumatic Brain Injury. CRC Press eBooks. https://doi.org/10.1201/9781439849828-10
613. Romesser, C. (2017). Delirium. CRC Press eBooks. https://doi.org/10.1201/9781315373904-8
614. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
615. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
616. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
617. Rowland, D. L., & Incrocci, L. (2008). Appendix: Alphabetical Listing of DSM‐IV Sexual and Gender Identity Disorders Reviewed. https://doi.org/10.1002/9781118269978.app1
618. Roy‐Byrne, P. (2015). Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2015.17.2/proybyrne
619. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
620. Runge, K., Elst, L. T. V., & Endres, D. (2019). Cerebrospinal fluid findings in adult patients with autism spectrum disorder. Pharmacopsychiatry. https://doi.org/10.1055/s-0039-1679145
621. Rupani, K., & Adarkar, S. (2022). Optimizing Patient Care in Sleep Disorders. Routledge eBooks. https://doi.org/10.4324/9780429030260-28
622. Sabo-Graham, T., & Seay, A. R. (1998). Consultation with the Specialist: Management of Status Epilepticus in Children. Pediatrics in Review. https://doi.org/10.1542/pir.19.9.306
623. Sadiq, H., & Abakah, S. (2015). Depression and Its Relation with Blood Group According Differences (Sex).
624. Saeed, S. A. (2009). Social Anxiety Disorder: An Update on Evidence-Based Treatment Options.
625. Saeed, S. A., & Tj, B. (1998). Panic disorder: effective treatment options.. PubMed.
626. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
627. Sahiner, V., & Akı, S. (2009). [Serotonin syndrome associated with linezolid use: a case report].. PubMed.
628. Salahuddin, M., Singh, P. K., Rathour, S., Jain, S., & Bijarnia, M. (2021). POOR CONFIDENCE DUE TO STAMMERING AND ITS HOMOEOPATHIC MANAGEMENT. International Journal of AYUSH.
629. Salaspuro, M. (2009). [Intoxicated patient at the emergency department and referral to treatment].. PubMed.
630. Salim, M. S., & Anjum, Q. (2003). Role of nerve blocks in chronic pain managementi. Rawal Medical Journal.
631. Sanchis‐Segura, C., & Spanagel, R. (2006). REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2006.00012.x
632. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
633. Sanz, G. L., Ruíz, E. C., & Vázquez, L. S. (2015). Síndrome confusional ag udo en pacientes de edad avanzada con fractura de fémur. Ágora de enfermería.
634. sarah, S. (2022). MANFAAT BUNGA LAVENDER BAGI PENDERITA INSOMNIA DAN CARA PENANGANAN PENYAKIT. https://doi.org/10.31219/osf.io/4za3q
635. Sarkar, S. (2016). Psychiatric Polypharmacy, Etiology and Potential Consequences. Current Psychopharmacologye. https://doi.org/10.2174/2211556005666160916124719
636. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
637. Sass, L. A. (2003). “Negative Symptoms,” Commonsense, and Cultural Disembedding in the Modern Age. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511616297.015
638. Sazonov, S. (2014). EPA-0651 – The complexity of psychopathological symptom as a possible indication of mental disease's etiology. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78023-x
639. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
640. Schildkrout, B. (2014). Disease #34: Mercury Poisoning. https://doi.org/10.1002/9781394260447.ch62
641. Schildkrout, B. (2014). Disease #53: Postconcussion Syndrome. https://doi.org/10.1002/9781394260447.ch81
642. Schildkrout, B. (2014). Disease #57: <scp>REM</scp> Sleep Behavior Disorder. https://doi.org/10.1002/9781394260447.ch85
643. Schildkrout, B. (2014). Disease #58: Restless Legs Syndrome. https://doi.org/10.1002/9781394260447.ch86
644. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
645. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
646. Schneider, G. (2020). Diagnostik von psychischen Faktoren bei chronischem Pruritus. Der Hautarzt. https://doi.org/10.1007/s00105-020-04596-1
647. Schneier, F. R., Bruce, L. C., & Heimberg, R. G. (2014). Social Anxiety Disorder (Social Phobia). American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg18
648. Schreiber, W. E. (2022). Introduction. https://doi.org/10.1002/9781119794080.ch1
649. Schulte, J. J., Hendricks, M., & Bienenfeld, D. (2010). Other Neurotic Disorders. https://doi.org/10.1002/9780470669600.ch103
650. Schumacher, S. (2012). Veränderungen somatosensorischer Funktionen bei asymptomatischen PINK1-Mutationsträgern und asymptomatischen PARKIN-Mutationsträgern im Vergleich zu gesunden Kontrollen.
651. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
652. Schweren, L. (2016). Stimulants and the developing brain.
653. Schäfer, I., Kurth, R., & Gerhardt, H. (2011). Posttraumatische und psychotische Symptome bei schwer traumatisierten Patienten. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0031-1281801
654. Scolding, N. (2010). Neurological complications of systemic disease. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.2420
655. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
656. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
657. Seeman, P., & Seeman, M. V. (2011). Schizophrenia and the supersensitive synapse. Neuropsychiatry. https://doi.org/10.2217/npy.11.18
658. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
659. Sergio, S. (2013). Adicciones y funcionamiento ejecutivo. Psicología y Psicopedagogía.
660. Seri, S., Cerquiglini, A., & Harding, G. F. A. (2006). Visually induced syncope: A nonepileptic manifestation of visual sensitivity?. Neurology. https://doi.org/10.1212/01.wnl.0000225058.42180.c2
661. Serrano, L., & Néstor, A. (2019). Proceso de Atención de Enfermería en neonato con diagnóstico de Síndrome de Abstinencia Neonatal, perteneciente al área CIN en el Hospital General Guasmo Sur..
662. Sesarini, C. (2015). GABAergic neurotransmission alterations in autism spectrum disorders. Neurotransmitter. https://doi.org/10.14800/nt.1052
663. Shah, R. R. (2005). Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.4.1.103
664. Sharma, A., Sorrell, J. H., & Peralta, N. R. (2007). A Protracted Case of Psychosis, Motor Abnormalities, and Agitation. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0211d
665. Sharpe, M. (2010). Chronic fatigue syndrome (postviral fatigue syndrome, neurasthenia, and myalgic encephalomyelitis). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260504
666. SheikhBahaei, S., Farhan, M., & Maguire, G. A. (2022). Improvement of stuttering after administration of methylphenidate - a case report. Personalized Medicine in Psychiatry. https://doi.org/10.1016/j.pmip.2022.100092
667. Shende, V., & Patel, F. R. (2014). AGMATINE AMELIORATES SOCIAL ISOLATION INDUCED OBSESSIVE-COMPULSIVE BEHAVIOR IN MICE.
668. Sher, L. (2015). Parental alienation: the impact on men’s mental health. International Journal of Adolescent Medicine and Health. https://doi.org/10.1515/ijamh-2015-0083
669. Shibasaki, H., & Hallett, M. (2016). Psychogenic Neurologic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190240974.003.0026
670. Shibasaki, H., Hallett, M., Bhatia, K. P., Reich, S. G., & Balint, B. (2020). Disorders of Increased Muscle Stiffness or Overactivity. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190865047.003.0009
671. Shirley, K. L., Norelli, L. J., & Smith, H. S. (2008). “Impulsology” <i>A New Paradigm for Addiction</i>. https://doi.org/10.1093/oso/9780195300550.003.0013
672. Shortland, P., & Mahns, D. A. (2016). Differing roles for parvalbumin neurons after nerve injury. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.189179
673. Sidhu, H., Venkatanarasimha, N., Bhatnagar, G., Vardhanabhuti, V., Fox, B., & Suresh, S. P. (2012). Imaging Features of Therapeutic Drug–induced Musculoskeletal Abnormalities. Radiographics. https://doi.org/10.1148/rg.321115041
674. Sikarwar, S. S., Daniel, K., & Jain, N. K. (2022). Synthesis, Characterization and Anti-Convulsant Activity of Novel Substituted Oxadiazole Derivatives. International Journal of Medical Sciences and Pharma Research. https://doi.org/10.22270/ijmspr.v8i2.39
675. Silva, T. D. O., Leite, J. R., Bezerra, W. D. S. P., Lima, M. B. L. D., & Fiorin, P. M. (2017). A DEPRESSÃO NA TERCEIRA IDADE:RELATO DE EXPERIÊNCIA DE UMA ATIVIDADE EDUCATIVA.
676. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
677. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
678. Simon, L., Patri, E., Gury, C., & Cousin, F. (2003). Pharmacologie et toxicologie cliniques de l'ecstasy. L information psychiatrique.
679. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
680. Slater, J. A. (2002). The medically ill child or adolescent. https://doi.org/10.1093/oso/9780195141733.003.0047
681. Slattery, A. P., Liebelt, E. L., & Gaines, L. A. (2014). Common ocular effects reported to a poison control center after systemic absorption of drugs in therapeutic and toxic doses. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000103
682. Smith, A. D., & Aronson, J. K. (2002). Adverse reactions to drugs. https://doi.org/10.1093/oso/9780192632340.003.0009
683. Smith, P. J., & Blumenthal, J. A. (2015). Exercise and Physical Activity in the Prevention and Treatment of Depression. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch8
684. Sn, L. (2003). [Importance of initial status of the nervous system in the developing of low intensity EMF exposure neuro-effects].. PubMed.
685. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
686. Solmi, M., Bortolato, B., Veronese, N., Stubbs, B., Herrmann, N., & Carvalho, A. F. (2019). Pharmacological Interventions for Cognitive Dysfunction in Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198810940.003.0018
687. Spence, S. A. (2006). All in the mind? The neural correlates of unexplained physical symptoms. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.12.5.349
688. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
689. Spreux‐Varoquaux, O. (2014). Le syndrome ou toxidrome sérotoninergique : étiologies, signes cliniques centraux et périphériques. L information psychiatrique. https://doi.org/10.1684/ipe.2013.1132
690. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
691. Stafstrom, C. E. (1995). Neonatal Seizures. Pediatrics in Review. https://doi.org/10.1542/pir.16.7.248
692. Stahl, S. M. (2002). Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression?. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v63n1101
693. Stahl, S. M., & Morrissette, D. A. (2018). Treatment of Secondary Behavioral Symptoms of Dementia. https://doi.org/10.1017/9781107706842.008
694. Standart, S., & Couteur, A. L. (2003). The Quiet Child: A Literature Review of Selective Mutism. Child and Adolescent Mental Health. https://doi.org/10.1111/1475-3588.00065
695. Stanford, S. C. (2001). Depression. https://doi.org/10.1002/0470846577.ch20
696. Staniloiu, A., & Markowitsch, H. J. (2013). 1699 – Long lasting personality changes after the onset of dissociative amnesia. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)76685-9
697. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
698. Sternbach, H., & State, R. C. (1997). Antibiotics: Neuropsychiatric Effects and Psychotropic Interactions. Harvard Review of Psychiatry. https://doi.org/10.3109/10673229709000304
699. Stohler, R., Rommelspacher, H., Ladewig, D., & Dammann, G. (1993). [Beta-carbolines (harman/norharman) are increased in heroin dependent patients].. PubMed.
700. Stoller, K. B. (2015). Psychiatric Co-occurring Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0015
701. Stone, J., & Carson, A. (2015). Conversion Disorder/Functional Neurological Disorder. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp009
702. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
703. Stübgen, J. (2002). Seizures in Multisystem Disease Affecting the Nervous System. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_4
704. Su, P., Tao, F., Sun, C., Zhu, Q. H., & Zhou, X. (2007). Analysis on the epidemiologic characteristics of mass hysteria in schools from 1995 to 2004 in China.
705. Sugiyama, H., & Kanba, S. (2001). [Symptomatology and diagnosis of depression].. PubMed.
706. Sumiyoshi, T., Matsuoka, T., & Kurachi, M. (2012). Role for Pituitary Neuropeptides in Social Behavior Disturbances of Schizophrenia. InTech eBooks. https://doi.org/10.5772/52326
707. Sun, M. (2018). Executive functioning: perspectives on neurotrophic activity and pharmacology. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000427
708. Sussman, S., & Ames, S. L. (2008). Concepts of Cessation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511500039.016
709. Swann, A. C. (2012). Impulsivity and Affective Regulation. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780195389715.013.0084
710. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
711. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
712. Taliyan, R., Singh, G., & Sharma, P. (2012). None. International Journal of Pharmaceutical Sciences and Research. https://doi.org/10.13040/ijpsr.0975-8232.3(10).3530-42
713. TASLI, B. A., Köse, S., Puşuroğlu, M., & Hocaoğlu, Ç. (2023). Psychotic Disorder Due to Methamphetamine Use in a Female Case. Bağımlılık Dergisi. https://doi.org/10.51982/bagimli.1100869
714. Taylor, C. A. (2003). Neuropsychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.023
715. Tedeschi, G., Russo, A., & Tessitore, A. (2015). Functional neuroimaging: the adaptive mechanisms in migraine. The Journal of Headache and Pain. https://doi.org/10.1186/1129-2377-16-s1-a6
716. Teja, N., Gummadi, O. D., Devi, B. V., & Pavani, N. (2020). Evaluation of Depressant Activity on Mansoa alliacea on Rats. Acta Scientific Pharmaceutical Sciences. https://doi.org/10.31080/asps.2020.04.0617
717. Terman, M., & Terman, J. S. (2013). Chronotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.026
718. Thanacoody, R. (2007). Serotonin syndrome. Adverse Drug Reaction Bulletin. https://doi.org/10.1097/01.fad.0000292087.11074.2f
719. Thomas, N., & Pantelis, C. (2015). Psychotic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp535
720. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
721. Tickner, N., Apps, J., Keady, S., & Sutcliffe, A. (2012). An overview of drug therapies used in the treatment of dystonia and spasticity in children. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/archdischild-2011-301170
722. Timperley, J., Leeson, P., Mitchell, A. R., & Betts, T. (2007). Chapter 6 Troubleshooting pacemakers. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198571322.003.0006
723. Tiwari, M. S. K., & Kushwaha, M. M. D. (2022). Adverse Effect of Non-Narcotic Drug on CNS and Visceral Organ. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-3081
724. Todd, O., & Teale, E. (2017). Delirium: a guide for the general physician. Clinical Medicine. https://doi.org/10.7861/clinmedicine.17-1-48
725. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
726. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
727. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
728. Torpy, J. M. (2008). Delirium. JAMA. https://doi.org/10.1001/jama.300.24.2936
729. Torpy, J. M. (2010). Delirium. JAMA. https://doi.org/10.1001/jama.304.7.814
730. Trevisan, L., Boutros, N. N., Petrakis, I. L., & Krystal, J. H. (1998). Complications of alcohol withdrawal: pathophysiological insights.. PubMed.
731. Trujillo, K. A. (2002). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_20
732. Trujillo, M. C. H., Arenas, M. V., & Villeros, J. J. B. (2019). Arte ¿cuáles son las repercusiones académicas y emocionales en el fallo de las funciones ejecutivas en niños con TDAH, TDA y las estrategias de intervención?.
733. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
734. Tsionos, I., & Viet, D. L. (2008). Nerve entrapment syndromes provoking motor deficits in the upper extremity. CRC Press eBooks. https://doi.org/10.3109/9780203091791-28
735. Tyagi, R., Singh, S., Joshi, A. M., Chopra, V., Vyas, P., & Gupta, A. (2020). Overview of Salvia divinorum –Substance-induced psychosis. International Journal of Research in Pharmaceutical Sciences. https://doi.org/10.26452/ijrps.v11ispl4.4360
736. Umaru, I. J., Innocent, N., & Umaru, K. I. (2024). Review: Neurochemical Aspects of Mental Health and Neurological Diseases. https://doi.org/10.58578/ajbmbr.v1i1.3473
737. Umut, G., Küçükparlak, İ., Özgen, G., & Türkcan, A. (2011). Esrar Kullanımı Sırasında Başlayan ve N, N- Dimetiltriptamin (Dmt) Kullanımı ile Psikotik Özellikler Eklenen Duygudurum Bozukluğu: Bir Olgu Sunumu / A Mood Disorder Episode with an Onset Under Chronic Cannabis Consumption, and Accompanied With Psychotic Features Immediately After N,N-Dimethyltryptamine (Dmt) Use: A Case Report. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. https://doi.org/10.5350/dajpn2011240312
738. Utari, F. P., Suyanti, T. S., & Karyawati, T. (2023). Asuhan Keperawatan Jiwa Pada Tn.M Dengan Masalah Utama Resiko Perilaku Kekerasan Akibat : Skizofrenia Tak Terinci Di Ruang Srikandi RSJD Dr.Amino Gondohutomo Provinsi Jawa Tengah. DIAGNOSA Jurnal Ilmu Kesehatan dan Keperawatan. https://doi.org/10.59581/diagnosa-widyakarya.v1i4.1305
739. Uysal, C., & Albayrak, Y. (2013). IMIPRAMINE INDUCED ACUTE DYSTONIA IN A CHILD WITH ENURESIS NOCTURNA.
740. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
741. Vanderver, A., Tonduti, D., Schiffmann, R., Schmidt, J., & Knaap, M. S. V. D. (1993). Leukodystrophy Overview – ARCHIVED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
742. Vandvik, I. H., & Skjeldal, O. H. (1994). [Conversion disorders in children and adolescents. A multidisciplinary approach].. PubMed.
743. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
744. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
745. Venkataraman, A., Turton, S., & Lingford‐Hughes, A. (2020). Drug use and associated neuropsychiatric conditions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198757139.003.0028
746. Ventriglio, A., Gentile, A. J., Baldessarini, R. J., & Bellomo, A. (2015). Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets. Current Pharmaceutical Design. https://doi.org/10.2174/1381612821666150105121244
747. Vergauwen, K. (2024). Physical activity, participation and health-related quality of life in chronic fatigue syndrome and multiple osteochondromas. https://doi.org/10.26481/dis.20240425kv
748. Verger, M. G. R. D. (2016). Aplicación de tecnologías asistenciales para el aumento de la capacidad de comunicación en personas afectadas de trastorno neuromotor.
749. Vicente, M. O., Gutiérrez, L. E. J. F., & Oves, M. I. R. (2011). ALCOHOLISMO CONSECUTIVO AL TRASTORNO DE PÁNICO. DOAJ (DOAJ: Directory of Open Access Journals).
750. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
751. Virmani, A., Ali, S. F., & Binienda, Z. (2010). Neuroprotective strategies in drug abuse‐evoked encephalopathy. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05171.x
752. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
753. Volpe, B. T. (1997). Delayed Neuronal Degeneration Results from Endogenous Glutamate Excess. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1997.tb48390.x
754. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
755. Wahyuni, A. A. S., WIGUNA, I. G. R. P., & Aditya, M. R. (2023). WAHAM SOMATIK : SEBUAH TINJAUAN PUSTAKA. Jurnal Hasil Penelitian dan Pengembangan (JHPP). https://doi.org/10.61116/jhpp.v1i3.156
756. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
757. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
758. Walther, M., & Woods, D. W. (2010). Trichotillomania. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1011
759. Wang, W., & Wang, J. (2017). Measurement of Nightmare Experience, and its Application in Research and Treatment of Psychiatric Disorders. Journal of Psychiatry. https://doi.org/10.4172/2378-5756.1000e111
760. Wehrman, E. C. (2022). Grief/Bereavement. The International Encyclopedia of Health Communication. https://doi.org/10.1002/9781119678816.iehc0883
761. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
762. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
763. Wenzel, T., & Zhu, L. (2013). Posttraumatic Stress in Athletes. https://doi.org/10.1002/9781118404904.ch10
764. Wf, B., & Cl, B. (1992). The safety profile of paroxetine.. PubMed.
765. White, D. M., Daniell, W., Maxwell, J. K., & Townes, B. D. (1990). Psychosis following styrene exposure: A case report of neuropsychological sequelae. Journal of clinical and experimental neuropsychology. https://doi.org/10.1080/01688639008401020
766. Widiger, T. A., & Oltmanns, J. R. (2017). Neuroticism is a fundamental domain of personality with enormous public health implications. World Psychiatry. https://doi.org/10.1002/wps.20411
767. Wiebe, D. J., Comstock, R. D., & Nance, M. L. (2011). Concussion research: a public health priority. Injury Prevention. https://doi.org/10.1136/ip.2010.031211
768. Wiemer‐Kruel, A. (2011). Antikonvulsive Pharmakotherapie bei Anfällen. PiD - Psychotherapie im Dialog. https://doi.org/10.1055/s-0031-1276981
769. Wiet, S. (2017). Origins of Addiction Predictably Embedded in Childhood Trauma: A Neurobiological Review. Journal of korean Academy of Child and Adolescent Psychiatry. https://doi.org/10.5765/jkacap.2017.28.1.4
770. Wijdicks, E. F. M. (2025). Neurology of Overdose. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197544976.003.0052
771. Wijdicks, E. F. M. (2025). “Blacked Out and Slumped Down”. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197544976.003.0007
772. Willner, P. (1984). Drugs, Biochemistry, and Conscious Experience: Toward a Theory of Psychopharmacology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1984.0009
773. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
774. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
775. Wojtyła-Buciora, P., Grzelak, T., Giermaziak, W., Mikołajczak, R., Kapka‐Skrzypczak, L., & Mądry, E. (2023). Novel Psychoactive Substances as a Vital and Ever-Changing Concern in Public Health. https://doi.org/10.2478/bgbl-2023-0016
776. Wolf, P. (2005). From Precipitation to Inhibition of Seizures: Rationale of a Therapeutic Paradigm. Epilepsia. https://doi.org/10.1111/j.0013-9580.2005.461005.x
777. Woo, S., & Keatinge, C. (2016). Neurodevelopmental Disorders I: Autism Spectrum Disorder. https://doi.org/10.1002/9781394259472.ch4
778. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
779. Yadav, P. K., & Panda, A. K. (2023). A case of toxin-induced neuromyotonia. Medicine India. https://doi.org/10.25259/medindia_20_2023
780. Yamauchi, T. (1998). Impairment of Consciousness During Epileptic Seizures with Special Reference to Neuronal Mechanisms. Epilepsia. https://doi.org/10.1111/j.1528-1157.1998.tb05144.x
781. Yan, R. M., Cardonne, M. M., Reyes, E. J. M., & Leyva, A. G. (2022). Herramienta para la obtención de Patrones de Conectividad Cerebral en Pacientes con Deterioro Cognitivo. Orange Journal. https://doi.org/10.46502/issn.2710-995x/2021.6.04
782. Yanai, K., & Hosaki, H. (1994). [Manic-depressive states induced by drugs and various diseases].. PubMed.
783. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
784. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
785. Yee, B. J., Liu, P. Y., Phillips, C. L., & Grunstein, R. R. (2013). Neuroendocrine aspects of sleep apnea. CRC Press eBooks. https://doi.org/10.3109/9781420020885-16
786. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
787. Yohannes, A. M., & Baldwin, R. (2008). Medical Comorbidities in Late-Life Depression.
788. Yoshimasu, K., Takemura, S., Fukumoto, J., & Miyashit, K. (2012). Self-Reported Symptoms Related to Depression and Suicidal Risk. InTech eBooks. https://doi.org/10.5772/31630
789. Youssef, P. E. (2022). Childhood Neurologic Conditions: Movement Disorders.. PubMed.
790. Yui, K. (2015). EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology. https://doi.org/10.2174/1570159x1306151126144423
791. Yutzy, S. H. (2015). Somatic Symptom and Related Disorders: Somatic Symptom Disorder, Illness Anxiety Disorder, and Conversion Disorder. Psychiatry. https://doi.org/10.1002/9781118753378.ch62
792. Yıldırım, A. (2015). An Unexpected Cause of Hyperactive Delirium in Patients with Decompensated Nonalcoholic Cirrhosis. Journal of Gastrointestinal & Digestive System. https://doi.org/10.4172/2161-069x.1000261
793. Zaatreh, M. (2003). Anticonvulsant-induced dyskinesia. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2.4.385
794. Zaccherini, G., Tufoni, M., Ricci, C. S., Tovoli, A., Napoli, L., & Domenicali, M. (2013). A look at the hepatic encephalopathy in cirrhosis. Reviews in Health Care. https://doi.org/10.7175/rhc.4474155-74
795. Zaccherini, G., Tufoni, M., Ricci, C. S., Tovoli, A., Napoli, L., & Domenicali, M. (2013). A look at the hepatic encephalopathy in cirrhosis. Reviews in Health Care. https://doi.org/10.7175/rhc.v4i1.447
796. Zanardi, G. (2024). Nuove frontiere nel trattamento delle dipendenze comportamentali. Proposte innovative e approcci integrati. RIVISTA SPERIMENTALE DI FRENIATRIA. https://doi.org/10.3280/rsf2024-003005
797. Zeller, J. L., Burke, A. E., & Glass, R. M. (2008). Acute Pain Treatment. JAMA. https://doi.org/10.1001/jama.299.1.128
798. Zheng, Z., Zou, K., Huang, J., Yang, J., Zhou, J., Xiong, R., & Li, Y. (2023). Schizophrenia. https://doi.org/10.1007/978-981-99-4538-2_20
799. Zhu, Y., Han, G., & Li, S. (2019). Chronic Fatigue Stress and Sudden Death. IntechOpen eBooks. https://doi.org/10.5772/intechopen.88649
800. Zoellner, L. A., Graham, B., & Bedard‐Gilligan, M. (2019). Trauma- and Stressor-Related Disorders. Routledge eBooks. https://doi.org/10.4324/9780429028267-10
801. Zúñiga, R. L. (2017). Delirium y la presencia de respuesta inflamatoria sistémica, descontrol glucémico e hipoxia en pacientes mayores de 65 años en el servicio de urgencias médicas del Hospital General de Pachuca..
802. Çiçek, A., Elibol, P., Bardak, Ş., Demiroğlu, O., Demir, G., Nalbant, T., Gökalp, G., & Berksoy, E. (2022). Delirium due to Anticholinergic Intoxication and Use of Physostigmine in Pediatric Emergency Room. Turkish Journal of Pediatric Emergency and Intensive Care Medicine. https://doi.org/10.4274/cayd.galenos.2021.32032
803. Şahin, C., Dursun, S., Çetin, M., & Arıcıoğlu, F. (2016). The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20160520092044
804. Şenel, G. B., & Karadeniz, D. (2022). Neuroanatomical and Etiological Approaches to Secondary Narcolepsy. Neurological Sciences and Neurophysiology. https://doi.org/10.4103/nsn.nsn_5_22
805. Šostar, Z., Vodanović, M., Breitenfeld, D., Breitenfeld, T., Buljan, D., & Granić, R. (2009). Composers - Substance Abusers. Alcoholism and psychiatry research Journal on psychiatric research and addictions.
806. Šumarac-Dumanović, M., Micić, D., Macut, Đ. P., Kendereški, A., Zorić, S., Cvijović, G., & Pejković, D. (2002). Hipoglikemijski sindromi - dijagnostički i terapijski pristup i prikaz dva slučaja. ABC - časopis urgentne medicine.
807. Оstroumova, Т. М., Kulikova, M., & De, V. (2022). Drug-induced hypertension. Medical alphabet. https://doi.org/10.33667/2078-5631-2022-3-8-13